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Chapter 5.1: Timing of renal replacement therapy
in AKI
Whether or not to provide RRT, and when to start, are two of
the fundamental questions facing nephrologists and inten-
sive-care practitioners in most cases of severe AKI. In recent
publications, the timing of initiation of RRTwas listed as one
of the top priorities in research on AKI.524 However, this
dimension has not been included as a factor in any of the
large RCTs in this area. The optimal timing of dialysis for
AKI is not defined. In current practice, the decision to start
RRT is based most often on clinical features of volume
overload and biochemical features of solute imbalance
(azotemia, hyperkalemia, severe acidosis). However, in the
absence of these factors there is generally a tendency to avoid
dialysis as long as possible, a thought process that reflects the
decisions made for patients with CKD Stage 5.
Clinicians tend to delay RRT when they suspect that
patients may recover on their own, and because of concern
for the well-known risks associated with the RRT procedure,
including hypotension, arrhythmia, membrane bioincom-
patibility, and complications of vascular access and anti-
coagulant administration. There is also some concern that
RRT may compromise recovery of renal function, and
increase the progression of CKD.525 Whether these risks
outweigh the potential benefits of earlier initiation of RRT is
still unclear.
5.1.1: Initiate RRT emergently when life-threatening
changes in fluid, electrolyte, and acid-base balance
exist. (Not Graded)
5.1.2: Consider the broader clinical context, the presence
of conditions that can be modified with RRT, and
trends of laboratory tests—rather than single BUN
and creatinine thresholds alone—when making the
decision to start RRT. (Not Graded)
RATIONALE
While no RCTs exist for dialysis for life-threatening
indications, it is widely accepted that patients with severe
hyperkalemia, severe acidosis, pulmonary edema, and uremic
complications should be dialyzed emergently. In the absence
of kidney function, and when therapeutic measures that
promote the intracellular shift of potassium (such as
correction of acidosis with bicarbonate, glucose and insulin
infusion, and beta-2 agonists) are exhausted, an excess of
potassium can only be eliminated with RRT. On the other
hand, when intermittent dialysis is used after these
therapeutic interventions, the extracorporeal removal of
potassium will be reduced and the post-treatment rebound
of serum potassium will be more pronounced.526
Metabolic acidosis is a frequent clinical problem in
patients with severe AKI. Although the discussion as to
when metabolic acidosis in critically ill patients should be
corrected is outside the scope of this guideline, metabolic
acidosis associated with AKI can usually be corrected with
bicarbonate and should rarely require urgent dialysis if not
accompanied by volume overload or uremia.527 As the pH
and bicarbonate values to initiate dialysis for metabolic
acidosis are not supported by evidence, no standard criteria
for initiating dialysis for acidosis exist. A variety of poisons,
drug overdoses, and toxic compounds (e.g., salicylates,
ethylene glycol, methanol, metformin) can contribute to
acid-base problems and also lead to AKI. In these circum-
stances, RRT may also facilitate removal of the offending
drug.528–530
Only one RCT has evaluated the effect of timing of
initiation of RRT on outcome. Bouman et al.531 randomized
106 critically ill patients with AKI to early vs. late initiation
of RRT. The early initiation group started RRT within
12 hours of oliguria (o30ml/h for 6 hours, not respond-
ing to diuretics or hemodynamic optimization), or CrCl
o20ml/min. The late-initiation group started RRT when
classic indications were met. The study did not find
differences in ICU or hospital mortality, or in renal recovery
among survivors, but was clearly too small to allow for
definitive conclusions (Suppl Table 30).
The remaining data come from observational studies. The
association of early initiation of dialysis with survival benefit
was first suggested by case series with historical controls
conducted in the 1960 s and 1970 s.532–535 In these studies,
levels of blood urea or BUN were used to distinguish early vs.
late start of dialysis. However, these studies mostly combined
early start with more-intensive dialysis and late start with
less-intensive dialysis. More recent studies have continued the
trend focusing on BUN as a biomarker for starting RRT.
Single-center observational studies that were restricted to
AKI after trauma536 and coronary artery bypass surgery537,538
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suggested a benefit to RRT initiation at lower BUN concen-
trations. A prospective multicenter observational cohort
study performed by the Program to Improve Care in Acute
Renal Disease (PICARD) analyzed dialysis initiation—as
inferred by BUN concentration—in 243 patients from five
geographically and ethnically diverse clinical sites. Adjusting
for age, hepatic failure, sepsis, thrombocytopenia, and SCr,
and stratified by site and initial dialysis modality, initiation of
RRT at higher BUN (476mg/dl [blood urea427.1mmol/l])
was associated with an increased risk of death (RR 1.85; 95%
CI 1.16–2.96).539 In a prospective multicenter observational
study conducted at 54 ICUs in 23 countries, timing of RRT
was stratified into ‘‘early’’ or ‘‘late’’ by median urea at the
time RRT started (24.2mmol/l [BUN 67.8mg/dl]), and also
categorized temporally from ICU admission into early (less
than 2 days), delayed (between 2–5 days), or late (more than
5 days). Timing by serum urea showed no significant
difference in mortality. However, when timing was analyzed
in relation to ICU admission, late RRT was associated with
greater crude mortality (72.8% late vs. 62.3% delayed vs. 59%
early, P¼ 0.001) and covariate-adjusted mortality (OR 1.95;
95% CI 1.30–2.92; P¼ 0.001). Overall, late RRT was asso-
ciated with a longer duration of RRTand stay in hospital, and
greater dialysis dependence.540 It is, however, not clear
whether AKI occurring later in the course of ICU stay has the
same pathophysiology and prognosis than AKI present on or
early after admission. The most recent study on this subject is
the analysis of surgical ICU patients with AKI, showing that
late initiation of RRT (defined as RIFLE-I or -F) was an inde-
pendent predictor of mortality (HR 1.846; CI 1.07–3.18).541
Traditional indications for RRT, developed for patients
with advanced CKD, are not necessarily valid in the context
of AKI. For instance, massive volume overload resulting from
volume resuscitation may be an indication for RRT even in
the absence of significant elevations in BUN or SCr. In this
instance, it may be more appropriate to consider dialytic
intervention in the ICU patient as a form of renal support
rather than renal replacement. Indeed, some of the
traditional indications for dialysis (e.g., uremic pericarditis,
pleuritis, encephalopathy, coagulopathy) would be consid-
ered ‘‘complications’’ of AKI rather than indications for RRT.
Additionally, the decision to start RRT should recognize the
goals of therapy, keeping in mind the therapeutic potential of
dialysis in general, and each dialysis modality in particular.
The treatment of AKI with RRT has the following goals: i) to
maintain fluid and electrolyte, acid-base, and solute homeo-
stasis; ii) to prevent further insults to the kidney; iii) to
permit renal recovery; and iv) to allow other supportive
measures (e.g., antibiotics, nutrition support) to proceed
without limitation or complication. Ideally, therapeutic inter-
ventions should be designed to achieve the above goals and a
systematic assessment of all these factors is key to determi-
ning the optimal timing for initiating dialysis (Table 17).
There is increasing evidence that fluid overload in critical
illness and AKI is associated with adverse outcomes,
especially in the pediatric setting.83,84,542–549 Whether this is
a causal relationship remains to be proven, although a
randomized trial in hemodynamically stable patients with
acute respiratory distress syndrome seems to suggest that
it is.549 Randomizing patients according to RRT initiation on
the basis of fluid status would allow this question to be
answered. A secondary analysis of a randomized trial
comparing IHD to CRRT showed that patients receiving
RRT predominantly for solute control experienced better
outcomes than those predominantly treated for volume
overload. Patients dialyzed for control of both azotemia and
volume overload experienced the worst outcome.550 Analysis
of a multicenter observational cohort showed that mean
daily fluid balance in AKI patients was significantly more
positive among nonsurvivors than survivors.84 Data from
the PICARD group examining 396 ICU patients with AKI
requiring RRT further supports these findings. Survivors had
lower fluid accumulation at dialysis initiation compared to
nonsurvivors (8.8% vs. 14.2% of baseline body weight;
P¼ 0.01 adjusted for dialysis modality and severity score).
The adjusted OR for death associated with fluid overload at
dialysis initiation was 2.07 (95% CI 1.27–3.37).83 These data
suggest that fluid overload should be further evaluated as
parameter to guide the initiation of RRT (see also Pediatric
Considerations).
Other factors that might influence the decision of when to
start RRT are the severity of the underlying disease (affecting
the likelihood of recovery of kidney function), the degree of
dysfunction in other organs (affecting the tolerance to e.g.,
fluid overload), the prevalent or expected solute burden (e.g.,
in tumor lysis syndrome), and the need for fluid input related
to nutrition or drug therapy (Table 17). Early detection and
accurate prediction of patients that ultimately will require
RRTmay allow earlier initiation in those who need it and, at
the same time, prevent harm in those who do not. Recent
evidence suggests a potential role for biomarkers in this field.
Plasma neutrophil gelatinase-associated lipocalin was shown
to have an area under the receiver operating characteristic
curve of 0.82 for the prediction of RRT requirement.551
Pediatric considerations
Provision of acute RRT to children requires special consi-
derations. Pediatric and adolescent patients range in age from
the premature neonate to 25 years of age, with a size range of
1.5–200 kg. In addition, the epidemiology of the pediatric
AKI has changed from primary kidney disease in the 1980 s to
injury resulting from another systemic illness or its treatment
(e.g., sepsis and nephrotoxic medications).552,553 Newborns
with inborn errors of metabolism who do not respond to
dietary and pharmacologic management require expeditious
dialytic removal of ammonia to decrease the risk of death and
long-term neurologic dysfunction,554 and infants who receive
surgical correction of congenital heart disease, often receive
PD early after cardiopulmonary bypass to prevent fluid
overload and/or minimize the proinflammatory response.
Finally, children develop multiorgan dysfunction very rapidly
in their ICU course, with the maximal organ dysfunction
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occurring with 72 hours and mortality occurring within 7
days of ICU admission, respectively.555,556 Thus, the issue of
timing of dialysis initiation is critically important in children.
Both recommendations in this section of the guideline are
applicable to pediatric patients. A detailed discussion of the
specific pediatric clinical situations is beyond the scope of
Table 17 | Potential applications for RRT
Applications Comments
Renal replacement This is the traditional, prevailing approach based on utilization of RRT when there is little or no residual kidney
function.
Life-threatening indications No trials to validate these criteria.
Hyperkalemia Dialysis for hyperkalemia is effective in removing potassium; however, it requires frequent monitoring of potassium
levels and adjustment of concurrent medical management to prevent relapses.
Acidemia Metabolic acidosis due to AKI is often aggravated by the underlying condition. Correction of metabolic acidosis with
RRT in these conditions depends on the underlying disease process.
Pulmonary edema RRT is often utilized to prevent the need for ventilatory support; however, it is equally important to manage pulmonary
edema in ventilated patients.
Uremic complications
(pericarditis, bleeding, etc.)
In contemporary practice it is rare to wait to initiate RRT in AKI patients until there are uremic complications.
Nonemergent indications
Solute control BUN reflects factors not directly associated with kidney function, such as catabolic rate and volume status.
SCr is influenced by age, race, muscle mass, and catabolic rate, and by changes in its volume of distribution due to
fluid administration or withdrawal.
Fluid removal Fluid overload is an important determinant of the timing of RRT initiation.
Correction of acid-base
abnormalities
No standard criteria for initiating dialysis exist.
Renal support This approach is based on the utilization of RRT techniques as an adjunct to enhance kidney function, modify fluid
balance, and control solute levels.
Volume control Fluid overload is emerging as an important factor associated with, and possibly contributing to, adverse outcomes
in AKI.
Recent studies have shown potential benefits from extracorporeal fluid removal in CHF.
Intraoperative fluid removal using modified ultrafiltration has been shown to improve outcomes in pediatric cardiac
surgery patients.
Nutrition Restricting volume administration in the setting of oliguric AKI may result in limited nutritional support and RRT allows
better nutritional supplementation.
Drug delivery RRT support can enhances the ability to administer drugs without concerns about concurrent fluid accumulation.
Regulation of acid-base
and electrolyte status
Permissive hypercapnic acidosis in patients with lung injury can be corrected with RRT, without inducing fluid overload
and hypernatremia.
Solute modulation Changes in solute burden should be anticipated (e.g., tumor lysis syndrome). Although current evidence is unclear,
studies are ongoing to assess the efficacy of RRT for cytokine manipulation in sepsis.
AKI, acute kidney injury; BUN, blood urea nitrogen; CHF, congestive heart failure; SCr, serum creatinine; RRT, renal replacement therapy.
Table 18 | Fluid overload and outcome in critically ill children with AKI
Author Cohort (N) Outcome P
Goldstein 2001545 Single-center (22) Survivors 16% FO Nonsurvivors 34% FO 0.03
Gillespie 2004544 Single-center (77) % FO 410% with OR death 3.02 0.002
Foland 2004543 Single-center (113) 3 organ MODS patients
Survivors 9% FO Nonsurvivors 16% FO
1.78 OR death for each 10% FO increase
0.01
Goldstein 2005546 Multicenter (116) 2+ organ MODS patients
Survivors 14% FO Nonsurvivors 25% FO
o20% FO: 58% survival
420% FO: 40% survival
0.002
Hayes 2009547 Single-center (76) Survivors 7% FO Nonsurvivors 22% FO
OR death 6.1 for 420% FO
0.001
Sutherland 2010548 Multicenter (297) o10% FO: 70% survival
10–20% FO: 57% survival
420% FO: 34% survival
OR 1.03 (1.01–1.05) per % FO
0.001
AKI, acute kidney injury; FO, fluid overload; MODS, multiple-organ dysfunction syndrome; OR, odds ratio.
Reprinted from Goldstein SL. Advances in pediatric renal replacement therapy for acute kidney injury. Semin Dial 2011; 24:
187–191 with permission from John Wiley and Sons560; accessed http://onlinelibrary.wiley.com/doi/10.1111/j.1525-139X.2011.00834.x/full
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this guideline, and the reader is referred to in-depth
reviews.557,558
Importantly, fluid overload has emerged as a significant
factor associated with mortality in children with AKI
requiring CRRT (Table 18), although the physiological link
between increasing percent volume overload and mortality is
not completely clear.543–548,559 The largest trial to assess this
relationship in children is a multicenter prospective study
showing that the percentage fluid accumulation at CRRT
initiation is significantly lower in survivors vs. non-survivors
(14.2 ± 15.9% vs. 25.4 ± 32.9%; Po0.03) even after
adjustment for severity of illness. This study also found a
significantly higher mortality in patient with 420% fluid
overload (58%) vs. o20% fluid overload (40%) at CRRT
initiation.546 One retrospective study, in pediatric patients
who received stem-cell transplantation and developed AKI,
suggested that survival may be improved by an aggressive use
of diuretics and early initiation of RRT. All survivors (n¼ 11)
maintained or remained with percentage fluid accumulation
o10%, with diuretics and RRT. Among the 15 nonsurvivors,
only 6 (40%) had percentage fluid accumulation o10% at
the time of death.559 The latest analysis on this issue
confirmed increased mortality with increasing fluid overload
in 297 children treated with RRT: 29.6% mortality with less
than 10% fluid overload, 43.1% with 10–20% fluid overload,
and 65.6% with 420% fluid overload.548 However, strong
evidence to suggest that preventing this fluid overload with
earlier RRT will improve outcome remains absent.
RESEARCH RECOMMENDATIONS
K Determine reproducible criteria (e.g., fluid overload,
biomarker level, severity score) to inform the decision to
start RRT in adult and pediatric AKI patients. Such
criteria may also permit the identification of patients who
will ultimately require RRT and hence limit uncertainty
around whether to begin therapy.
K Determine whether early vs. late start of RRT, based on
the above-mentioned criteria, results in improved clinical
outcomes (e.g., mortality, evolution to CKD Stage 5) of
AKI patients.
SUPPLEMENTARY MATERIAL
Supplementary Table 30: Summary table of RCTs examining the effect
of early vs. late CVVH in the treatment of AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 5.2: Criteria for stopping renal replacement
therapy in AKI
Although many patients with AKI recover kidney function
sufficiently to be independent of RRT, discontinuation of
RRT in AKI has received little attention in the literature. The
decision whether or when to stop RRT in a patient with AKI
needs to consider an improvement in kidney function
adequate to meet demand, an improvement in the disorder
that prompted kidney support or futility. It is evident
that each of these events is influenced by the initial
indication for starting RRT and is subject to individual
variation. The strategy for stopping RRT requires considera-
tion of additional factors and often involves a modality
transition.
5.2.1: Discontinue RRT when it is no longer required,
either because intrinsic kidney function has recov-
ered to the point that it is adequate to meet patient
needs, or because RRT is no longer consistent with
the goals of care. (Not Graded)
RATIONALE
Many, but not all, patients requiring RRT will recover
enough function not to require long-term RRT. 21,394,561
The mean duration of RRT in two recent large RCTs
was 12–13 days.562,563 Thus, daily assessment of both
intrinsic kidney function and the ongoing appropriate-
ness of RRT consistent with the goals of therapy for the
patient are required. More than 50% of patients with severe
AKI will not improve, despite appropriate therapy. The
incidence of withdrawal of life-support treatments in
critically ill patients with multiorgan failure has increased
over the last decade.564 In addition to vasoactive medication,
mechanical ventilation, and artificial nutrition, RRT is one of
the therapies most likely to be discontinued during with-
drawal of life support. In general, decisions to withdraw
therapy occur in 10% of all patients from general ICUs, and
are responsible for roughly 40% of all deaths. Analysis of a
database of 383 AKI patients shows withdrawal of life
support in 72% of deaths.565 In another single-center
retrospective study involving 179 AKI patients requiring
RRT, therapy was withheld or withdrawn in 21.2%.566 A
posthoc analysis of the BEST KIDNEY database showed that
CRRT was withdrawn in 13% of the patients, representing
29% of those who died while on CRRT and 21% of all
nonsurvivors.196
Assessment of kidney function during RRT is not easy and
will depend on the modality used. In IHD, the fluctuations of
solute levels prevent achieving a steady state and thus exclude
the use of clearance measurements. Native kidney function
can only be assessed during the interdialytic period by
evaluating urine volume, urinary excretion of creatinine, and
changes in SCr and/or BUN values. However, one must
realize that intermittent treatment will be associated with
post-treatment rebound in solute levels, and that changes
in BUN and creatinine levels can also be modified by
nonrenal factors, such as volume status and catabolic rate.
In CRRT, continuous solute clearance of 25–35ml/min will
stabilize serum markers after 48 hours. This allows more
reliable measurements of CrCl by the native kidneys during
CRRT.
Very few investigators have looked at urine CrCl values as
a guide for CRRT withdrawal. One small retrospective study
(published as abstract) demonstrated that a CrCl (measured
over 24 hours) 415ml/min was associated with successful
termination of CRRT, defined as the absence of CRRT
requirement for at least 14 days following cessation.567
Further prospective trials will be needed to support these
findings. A large prospective observational study showed
that, in 529 patients who survived the initial period of CRRT,
313 were successfully removed from RRT, whereas 216
patients needed ‘‘repeat CRRT’’ within 7 days of discontinua-
tion. Multivariate logistic regression identified urine output
as the most significant predictor of successful termination
(OR 1.078 per 100ml/d). Not surprisingly, the predictive
ability of urine output was negatively affected by the use
of diuretics.196 Another retrospective observational analysis
showed that, of a total of 304 patients with postoperative
AKI requiring RRT (IHD), 31% could be weaned for more
than 5 days and 21% were successfully weaned for at least
30 days. Independent predictors for restarting RRT within
30 days were longer duration of RRT, a higher Sequential
Organ Failure Assessment score, oliguria, and age 465
years.568 In other words, urine output seems to be a very
important predictor of successful discontinuation of RRT.
Whether too-early discontinuation of RRT, requiring
reinstitution, is by itself harmful has not been properly
investigated. The above-mentioned observational studies
found a higher mortality in patients who needed to be
retreated with RRT (42.7% vs. 28.5%196 and 79.7% vs.
40%568). It is, however, not clear whether failure to wean is
simply a marker of illness severity or contributed by itself to
the adverse outcome.
The process of stopping RRT may consist of simple
discontinuation of RRT, or may include a change in the
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modality, frequency, or duration of RRT. For example,
switching from CRRT to IHD, or decreasing the frequency of
IHD from daily to every other day, represents different
methods of testing the ability of the patient’s own kidney to
take over. No specific guidance can be provided for how to
manage the transition of RRT from continuous to inter-
mittent. Evidence from large observational studies suggests
that large variation in practice exists.196
5.2.2: We suggest not using diuretics to enhance kidney
function recovery, or to reduce the duration or
frequency of RRT. (2B)
RATIONALE
The role of diuretics in the prevention and treatment of AKI
has already been discussed in Chapter 3.4. Only one RCT has
evaluated the potential role of diuretics in resolving AKI in
patients receiving RRT. After the end of the CVVH session,
the urine of the first 4 hours was collected for measuring
CrCl. Seventy one patients were subsequently randomized to
receive furosemide (0.5mg/kg/h) or placebo by continuous
infusion, continued until CrCl reached 30ml/min. Urinary
fluid losses were compensated by i.v. infusion. The primary
end-point was renal recovery (CrCl 430ml/min or stable
SCr without RRT) in the ICU and in the hospital. CVVH
was restarted based on predefined criteria. Patients treated
with furosemide (n¼ 36) had a significantly increased
urinary volume and greater sodium excretion compared to
placebo-treated patients (n¼ 35). However, there were no
differences in need for repeated CVVH, or renal recovery
during ICU or hospital stay.195 An observational study of
discontinuation of RRT also found no difference in diuretic
use between patents with successful or unsuccessful dis-
continuation of IHD.568 In summary, diuretics may improve
urine volume after RRT, but do not appear to have any
significant benefit in reducing the need for RRTor promoting
renal recovery from AKI.
Pediatric considerations
The medical indications guiding discontinuation of RRT in
children do not differ from adults, except in those instances
where RRT is initiated for pediatric-specific disease, such as
inborn errors of metabolism to treat hyperammonemia557 or
immediately after surgical correction of congenital heart
disease to maintain euvolemia, and/or possibly mitigate the
postbypass proinflammatory response.558
Prognosis in children who survive an AKI episode is
significantly better than in adults, and many children may have
several decades of life expectancy. Askenazi demonstrated nearly
80% 3- to 5-year survival for children discharged after an AKI
episode from a tertiary center,569 yet two-thirds of deaths occur-
red in the first 2 years after discharge, suggesting a high prob-
ability of greater life expectancy after that period. In addition, no
data exist to define a maximal RRT duration; even data from the
Prospective Pediatric CRRT Registry show 35% survival in
children receiving CRRT for428 days.570 Finally, since pediatric
AKI now results more often as a secondary phenomenon from
another systemic illness or its treatment,552,553 determination of
the overall goals of therapy for children, as in for adults, must
take into consideration local standards, patient and family
wishes, as well as the probability of recovery of the underlying
illness leading to AKI and the need for RRT.
RESEARCH RECOMMENDATIONS
K Determine clinical parameters (e.g., parameters of kidney
function, fluid overload, hypercatabolism) that predict
successful discontinuation of RRT in AKI patients.
K Determine biomarkers that may indicate renal recovery,
and whether their levels can be used to guide disconti-
nuation of RRT.
K Determine more reliable predictors of long-term out-
comes (e.g., mortality, quality of life) in AKI patients
(including clinical severity scores, biomarkers, machine
learning techniques, or combinations of these), that—
after validation in large cohorts—could be helpful
adjuncts in the decision to withdraw treatment.
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Chapter 5.3: Anticoagulation
In patients with AKI requiring RRT, the contact of blood with
the foreign surface of the extracorporeal circuit results in
activation of both the intrinsic and the extrinsic pathway of
plasmatic coagulation and activation of platelets.571 Preven-
tion of dialyzer/hemofilter clotting often requires some
form of anticoagulation, which may represent a particular
challenge in patients with AKI. The need for continuous
anticoagulation represents a potential drawback of CRRT.
5.3.1: In a patient with AKI requiring RRT, base the
decision to use anticoagulation for RRT on assess-
ment of the patient’s potential risks and benefits
from anticoagulation (see Figure 17). (Not Graded)
5.3.1.1: We recommend using anticoagulation
during RRT in AKI if a patient does
not have an increased bleeding risk or
impaired coagulation and is not already
receiving systemic anticoagulation. (1B)
RATIONALE
The goal of anticoagulation with RRT is to prevent clotting of
the filter and/or reduction in membrane permeability, and
thus to achieve adequate RRT and to prevent blood loss in
the clotted filter. These benefits have to be weighed against
the risk of bleeding, and economic issues, such as workload
and costs.
Patients with impaired coagulation (e.g., thrombocytopenia,
or prolonged prothrombin time or activated partial thrombo-
plastin time [aPTT]), due to underlying diseases such as liver
failure or dilution coagulopathy, may not benefit from
additional anticoagulation for RRT. In two recent large trials
50–60% of AKI patients requiring RRT were treated without
anticoagulant.562,563 While filter performance was not assessed,
adequate CRRT filter survival without anticoagulation has
mostly been described in patients with coagulopathies.572–575
However, no specific cut-off points have been determined for
platelet count, aPTT, International Normalized Ratio, fibrino-
gen, or other coagulation factors that would indicate the
possibility to perform RRT without anticoagulation. On the
other hand, prolonged clotting times can also point to a con-
sumptive coagulopathy based on the presence of an activated
coagulation. In these patients, frequent filter clotting will occur
and necessitate a switch to some form of anticoagulation.576
In patients that are treated without anticoagulation,
special attention is required to non-anticoagulant strategies
to prolong filter survival. These include a good functioning
vascular access, the reduction of blood viscosity and
hemoconcentration by saline flushes, predilution, high blood
flow rates, diffusive treatment, the reduction of blood-air
contact in the bubble trap, and assuring prompt reaction to
alarms.577,578
Many patients with AKI require systemic anticoagulation
for their underlying diseases (e.g., artificial heart valve, acute
coronary syndrome, atrial fibrillation). It is evident that, in
most instances, these patients will not require additional
anticoagulation for RRT; however, this should be assessed on
a case-by-case basis.
5.3.2: For patients without an increased bleeding
risk or impaired coagulation and not already
receiving effective systemic anticoagulation, we
suggest the following:
5.3.2.1: For anticoagulation in intermittent RRT,
we recommend using either unfractio-
nated or low-molecular-weight heparin,
rather than other anticoagulants. (1C)
5.3.2.2: For anticoagulation in CRRT, we sug-
gest using regional citrate anticoagula-
tion rather than heparin in patients
who do not have contraindications for
citrate. (2B)
5.3.2.3: For anticoagulation during CRRT in
patients who have contraindications for
citrate, we suggest using either unfractio-
nated or low-molecular-weight heparin,
rather than other anticoagulants. (2C)
RATIONALE
Worldwide, unfractionated heparin is still the most widely
used anticoagulant. Many European centers, however, have
switched from unfractionated to low-molecular-weight
heparin for routine anticoagulation during IHD.579 Advan-
tages and disadvantages of each type of heparin are
summarized in Table 19.
A recent meta-analysis of 11 RCTs comparing unfractio-
nated to low-molecular-weight heparin in chronic IHD
concluded that both are equally safe in terms of bleed-
ing complications (RR 0.96; CI 0.27–3.43) and as effective
in preventing extracorporeal thrombosis (RR 1.15; CI
0.7–1.91).586 Mainly because of the convenience of using a
single bolus injection at the start of IHD, the reduced risk of
heparin-induced thrombocytopenia (HIT), and of long-term
side-effects such as abnormal serum lipids, osteoporosis, and
hypoaldosteronism, the European practice guideline for
prevention of dialyzer clotting suggests using low-molecu-
lar-weight rather than unfractionated heparin in chronic
dialysis patients.587 Many European centers have extrapolated
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this to IHD for AKI, although studies in this setting are
lacking. In patients with AKI, the dose of heparin for IHD
and the target aPTT should be individualized according to
the presence or absence of coagulation abnormalities and/or
risk of bleeding.588,589 Monitoring should also include
platelet count, allowing timely detection of HIT.581 Since
low-molecular-weight heparins rely on the kidney as primary
route of elimination, patients with kidney injury are at risk
of accumulation and bleeding complications, depending
on the degree of kidney injury, and the dose and type of
low-molecular-weight heparin.590 The American College of
Chest Physicians (ACCP) guidelines for antithrombotic and
thrombolytic therapy therefore suggest using unfractionated
instead of low-molecular-weight heparin in patients with
severe renal insufficiency (CrCl o30ml/min) who require
therapeutic anticoagulation, or to reduce the dose of low-
molecular-weight heparin by 50%.580 The doses of low-
molecular-weight heparin that are required for IHD are
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Figure 17 | Flow-chart summary of recommendations. Heparin includes low-molecular-weight or unfractionated heparin.
CRRT, continuous renal replacement therapy; RRT, renal replacement therapy.
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lower than those required for therapeutic anticoagulation.
The doses of low-molecular-weight heparin, as provided by
the manufacturers, should be adapted to the bleeding risk of
the individual patient. Dose reduction may also be required
in patients receiving daily dialysis, which increases the risk
of accumulation. Since many patients with AKI require
prophylaxis for deep-vein thrombosis, scheduling this
prophylactic (or a slightly higher) dose at the beginning of
the dialysis session may serve the two purposes. Periodic
measurement of anti–Factor Xa levels may be useful with
prolonged use.
Alternative anticoagulants for IHD include protease
inhibitors such as nafamostate and platelet inhibitors such
as prostacyclin or its analogues. Randomized trials compar-
ing these anticoagulants/antiaggregants with heparin in the
setting of IHD for AKI are not available, and their use in
clinical practice is limited. Nafamostat is a protease inhibitor
that is mainly used in Japan and not available in the USA or
Europe. Small observational trials in chronic dialysis patients
with increased bleeding risk suggest a reduced bleeding
incidence.591–593 Concerns with nafamostat include the
absence of an antidote, and side-effects such as anaphylaxis,
hyperkalemia, and bone marrow suppression.594–596 Cross-
over comparisons of prostacyclin with low-molecular-weight
heparin in chronic dialysis patients show reduced effi-
ciency.597 A small trial showed reduced bleeding complica-
tions compared to low-dose heparin; however, at the expense
of slightly more premature terminations.598 Additional
drawbacks are systemic hypotension and the high costs.
Therefore, the routine use of alternative anticoagulants can
not be recommended in patients with AKI.
The anticoagulant effect of sodium citrate relies on
forming a complex with ionized calcium, thus removing an
essential component of the coagulation cascade. Part of the
citrate is removed in the extracorporeal circuit. Citrate
reaching the systemic circulation is rapidly metabolized in
the liver, muscle, and kidney, liberating the calcium and
producing bicarbonate. The buffering effect of sodium citrate
is proportional to the sodium ions it contains: a mole of
trisodium citrate produces the same buffering effect as
3moles of sodium bicarbonate; whereas preparations of
citrate, including hydrogen citrate, have proportionally less
buffering effect. Extracorporeal losses of calcium have to be
compensated by an exogenous infusion. Additional compli-
cations of citrate are summarized in Table 19. Regional citrate
anticoagulation requires a strict protocol, adapted to the local
treatment modality and flow settings. The protocol should
include instructions for the infusion of citrate and calcium,
for the composition of the dialysate/replacement fluid, and
for intensive metabolic monitoring, including acid-base
status, sodium, and total and ionized calcium levels.
Five randomized trials have compared citrate to heparins
during CRRT (Suppl Tables 31 and 32). For ethical reasons,
these trials were performed in patients without increased
bleeding risk. The first trial by Monchi et al. used a crossover
design to compare anticoagulation with unfractionated
heparin or citrate in 20 patients treated with postdilution
CVVH. Patients with high bleeding risk, liver cirrhosis, and
sensitivity to heparin were excluded. Forty-nine filters were
evaluated. Citrate was titrated to achieve a postfilter ionized
calcium level below 1.20mg/dl (0.3mmol/l). The dosing
regimen of heparin consisted of a bolus of 2000 to 5000 U,
Table 19 |Overview of the advantages and disadvantages of different anticoagulants in AKI patients
Anticoagulant Advantage Disadvantage References
Heparin (unfractionated) Wide availability Narrow therapeutic index – risk of bleeding
580,581
Large experience Unpredictable kinetics – monitoring required
Short half-life HIT
Antagonist available Heparin resistance
Monitoring with routine tests
(aPTT or ACT)
Low costs
Low-molecular-weight
heparin
More predictable kinetics
– Weight-based dosing possible
Risk of accumulation in kidney failure
580,582–584More reliable anticoagulant response
– No monitoring required
Monitoring requires nonroutine test (anti–Factor Xa)
Single predialysis dose may be
sufficient in IHD
Different drugs not interchangeable
Reduced risk of HIT Incomplete reversal by protamine
In most countries more expensive than unfractionated heparin
Citrate Strict regional anticoagulation
– reduced bleeding risk
Risk of accidental overdose with potentially fatal consequences
585
Insufficient citrate metabolism in patients with reduced liver
function and shock states resulting in accumulation with metabolic
acidosis and hypocalcemia
Other metabolic complication (acidosis, alkalosis, hypernatremia,
hypocalcemia, hypercalcemia)
Increased complexity
Requires strict protocol
aPTT, activated partial thromboplastin time; ACT, activated clotting time; HIT, heparin-induced thrombocytopenia; IHD, intermittent hemodialysis
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followed by a continuous infusion of 500–2000 U/h, aiming
at an aPTTof 60–80 seconds. Despite this rather high heparin
dose, the citrate group had a longer filter lifetime and less
spontaneous filter failure. Fewer patients in the citrate group
required transfusion, and the number of transfused units was
also lower. One patient in the heparin group experienced
bleeding and one patient in the citrate group had metabolic
alkalosis.599
The second trial randomized 30 patients with AKI
undergoing predilution continuous venovenous hemodiafil-
tration (CVVHDF) to anticoagulation with citrate or
unfractionated heparin. Patients with contra-indications to
one of the two anticoagulants (mainly high bleeding risk/
severe coagulopathy or metabolic problems that might be
aggravated by citrate) or who required systemic antic-
oagulation for medical reasons were excluded. Heparin was
titrated to achieve an aPTT of 45–65 seconds. Citrate was
titrated to a postfilter ionized calcium between 1.0–1.40mg/dl
(0.25–0.35mmol/l). Two patients in each group crossed over
to the other anticoagulant and these filters were not included
in the analysis. The trial was stopped early after 79 filters
because of an advantage using citrate, which resulted in a
significantly improved filter survival (124.5 hours vs. 38.3
hours; Po0.001). In addition, significantly less citrate-
anticoagulated filters were terminated for clotting (16.7%
vs. 53.5%). The incidence of bleeding also tended to be lower
with citrate (RR 0.17; CI 0.03–1.04; P¼ 0.06), but transfusion
requirement was not significantly different. Three patients in
the citrate group had metabolic alkalosis and two had
hypocalcemia.600
The third trial randomized 48 patients with AKI, treated
with CVVH, to citrate or unfractionated heparin. Patients
requiring systemic anticoagulation for medical reasons and
patients with high bleeding risk, severe coagulopathy, circulatory
failure, liver failure, or hypocalcemia were excluded (n¼ 12).
A total of 142 circuits was analyzed. Heparin was administered
as a bolus of 3000–5000 U followed by a continuous infusion of
1500 U/h adjusted to achieve an aPTTof 50–70 seconds. Citrate
(500mmol/l) was titrated to a postfilter ionized calcium
between 1.0–1.20mg/dl (0.25–0.30mmol/l). Neither circuit
survival nor the reasons for disconnecting the CVVH circuit
differed significantly between the two groups. However, the
number of major bleedings and the need for transfusion was
significantly greater in the heparin group. Two cases of
metabolic alkalosis were noted in the heparin group and two
episodes of hypocalcemia in the citrate group.601 Findings from
two studies published after the cut-off date for our literature
review are consistent with recommendation 5.3.2.2.601a,601b
A small randomized crossover study compared citrate
anticoagulation to regional heparinization in 10 CVVH
patients. Both treatment arms had a relatively short filter life
(13 hours for regional heparinization and 17 hours for
citrate) that did not differ significantly. No bleeding occurred
in either group.602
In the largest and most recent randomized trial, 200 patients
treated with postdilution CVVH were randomized to citrate or
the low-molecular-weight heparin, nadroparin. Again, patients
with bleeding risk or liver cirrhosis were excluded. Nadroparin
was started with a bolus of 2850 U followed by 380 U/h without
further monitoring. Citrate (500mmol/l) was administered at a
dose of 3mmol per liter blood flow, without monitoring of
postfilter ionized calcium. The primary outcomes were safety,
defined as the absence of adverse events necessitating disconti-
nuation of the study anticoagulant, and efficacy, defined as circuit
survival. Safety was significantly better in the citrate group with
only two patients requiring a change in anticoagulation regimen
vs. 20 patients in the nadroparin group (P40.001). Adverse
events were citrate accumulation (n¼ 1) and early clotting due to
protocol violation (n¼ 1) in the citrate group, and bleeding
(n¼ 16) or severe thrombocytopenia (n¼ 4) in the nadroparin
group. Circuit survival did not significantly differ. A computer-
driven combination of buffered and nonbuffered replacement
fluids was used in the citrate group, explaining why metabolic
alkalosis occurred more frequently in the nadroparin group.
Rather surprisingly, the authors also found an improved renal
recovery and an improved hospital survival in the citrate group.
This could not be attributed to differences in severity of illness,
nor in bleeding or transfusion requirement, and requires further
investigation.603
Metabolic complications were infrequent in these rando-
mized trials. In observational trials, the most frequent
metabolic complication is metabolic alkalosis, occurring in
up to 50% of the patients.604–606 In recently published surveys
or large clinical trials, the use of regional citrate antic-
oagulation is still limited to 0–20% of the patients/
treatments.562,563,607
A major contra-indication for the use of citrate antic-
oagulation is severely impaired liver function or shock with
muscle hypoperfusion, both representing a risk of citrate
accumulation. Markedly reduced citrate clearances and lower
ionized calcium levels have been found in patients with acute
liver failure or with severe liver cirrhosis.608–610 These patients
were excluded in all the randomized trials. In patients at risk,
intensified monitoring is recommendable. The ratio of total
to ionized calcium appears to be the best parameter to detect
citrate accumulation611,612 with an optimal cutoff at 2.1.613
Another important drawback of citrate anticoagulation, that
might influence the decision to implement it in routine
clinical practice, is the increased complexity of the procedure,
with risk of metabolic complications and the need for a strict
protocol adapted to the local RRT modality. We, therefore,
only recommend the use of citrate for anticoagulation during
CRRT in patients that do not have shock or severe liver
failure, and in centers that have an established protocol for
citrate anticoagulation.
Unfractionated heparin still remains the most widely used
anticoagulant during CRRT,562,563,607 mostly administered as
a prefilter infusion, with large variability in the administered
doses. When choosing a dose of heparin, the clinician should
realize that the relationship among heparin dose, aPTT, filter
survival, and bleeding complications is not straightfor-
ward,574,614–619 but it is common practice to measure aPTT
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for safety reasons and to adapt the target to the bleeding risk
of the patient.
Only two small prospective RCTs have compared un-
fractionated to low-molecular-weight heparin for anti-
coagulation during CRRT in patients with AKI and, thus,
no firm recommendations can be made. The first trial
randomized 47 patients with AKI or systemic inflammatory
response syndrome undergoing CVVHDF to heparin, start-
ing with a bolus of 2000–5000 U followed by an infusion of
10 U/kg/h titrated to an aPTT of 70–80 seconds, or to
dalteparin administered as bolus of 20 U/kg followed by an
infusion of 10 U/kg/h. The mean aPTT in the heparin group
was 79 seconds. The mean anti–Factor Xa level, determined in
six patients in the dalteparin group, was 0.49U/ml. Only 37
of the 82 tested filters were stopped for coagulation. There
was no difference in filter survival (with electively discon-
tinued filters being censored). The mean time to filter failure
was 46.8 hours in the dalteparin group and 51.7 hours in the
heparin group (NS). Three patients in each group had
bleeding, with no difference in transfusion requirement
between the two groups. Daily costs, including the coagula-
tion assays, were 10% higher with dalteparin.620
The second trial used a crossover design in 40 patients
with normal coagulation parameters undergoing predilution
CVVH. Patients treated with unfractionated heparin received
a bolus of 30 U/kg followed by a continuous infusion of
7 U/kg/h titrated to achieve an aPTT of 40–45 seconds.
Enoxaparin was given as an initial bolus of 0.15mg/kg
followed by a continuous infusion of 0.05mg/kg/h, adjusted
to an anti–Factor Xa level of 0.25–0.30U/ml. In the 37
patients that completed both treatment arms, mean filter life
was 21.7 hours with heparin and 30.6 hours with enoxaparin
(P¼ 0.017). A similar difference was found in the per-
protocol analysis. The incidence of bleeding was low and not
different between the two anticoagulants. Filter life did not
correlate with aPTT or anti–Factor Xa level. Costs were
similar in the two groups.616 Interestingly, these clinical
studies did not find a correlation between anti–Factor Xa
levels and filter life, questioning the value of anti–Factor Xa
monitoring with regard to efficacy.616,621 However, if used for
more than a few days, monitoring might be useful to detect
accumulation.
Alternative anticoagulants for use during CRRT include
the protease inhibitor nafamostate and the platelet inhibitors,
prostacyclin and analogues. Both have a short half-life and a
low MW, with the theoretical advantage of extracorporeal
elimination and reduced systemic anticoagulation. Nafamo-
stat is not available in the USA and Europe; there is no
antidote and several side-effects (agranulocytosis, hyperkale-
mia, anaphylactoid reactions) have been described.594–596 A
few small trials showed improved filter survival during CRRT
when adding prostaglandins to heparin compared to heparin
alone.622–624 However, prostaglandins appear to have a
limited efficacy when used alone, induce systemic hypoten-
sion,625,626 and are expensive. Their use during CRRT can
therefore not be recommended.
5.3.3: For patients with increased bleeding risk who are
not receiving anticoagulation, we suggest the
following for anticoagulation during RRT:
5.3.3.1: We suggest using regional citrate anti-
coagulation, rather than no anticoagula-
tion, during CRRT in a patient without
contraindications for citrate. (2C)
5.3.3.2: We suggest avoiding regional heparini-
zation during CRRT in a patient with
increased risk of bleeding. (2C)
RATIONALE
The risk of bleeding is considered high in patients with recent
(within 7 days) or active bleeding, with recent trauma or
surgery (especially in head trauma and neurosurgery), recent
stroke, intracranial arteriovenous malformation or aneurysm,
retinal hemorrhage, uncontrolled hypertension, or presence
of an epidural catheter. In these patients, the benefit of
anticoagulation may not outweigh the risk of bleeding,
and they should (at least initially) be treated without
anticoagulation, or with CRRT with regional citrate anti-
coagulation.
We suggest performing RRT without anticoagulation in
patients with increased bleeding risk. A possible exception
can be made for patients who do not have contraindications
for citrate. Randomized trials comparing citrate with
heparins have been performed in patients without increased
bleeding risk. However, since citrate results in strictly regional
anticoagulation, it seems reasonable to also suggest its use
during CRRT in AKI patients with increased bleeding risk.
Another approach to achieve regional anticoagulation is
regional heparinization combining a prefilter dose of heparin,
aiming at a prolongation of the extracorporeal aPTT, with
postfilter neutralization with protamine, aiming at normali-
zing the systemic aPTT. This procedure has been described in
chronic dialysis and CRRT,572,573,624,627,628 but has not been
studied with much scrutiny. It is cumbersome and difficult to
titrate because heparin has a much longer half-life than
protamine, inducing a risk of rebound. In addition, it exposes
the patient to the side-effects of both heparin (mainly the risk
of HIT) and protamine (mainly anaphylaxis, platelet dysfunc-
tion, hypotension, and pulmonary vasoconstriction with right
ventricular failure)629 and is therefore not recommended.
5.3.4: In a patient with heparin-induced thrombocytopenia
(HIT), all heparin must be stopped and we
recommend using direct thrombin inhibitors (such
as argatroban) or Factor Xa inhibitors (such as
danaparoid or fondaparinux) rather than other or
no anticoagulation during RRT. (1A)
5.3.4.1: In a patient with HIT who does not have
severe liver failure, we suggest using
argatroban rather than other thrombin
or Factor Xa inhibitors during RRT. (2C)
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RATIONALE
Immune-mediated HIT results from antibodies directed
against the complex of heparin and platelet factor 4, and
occurs in 1–3% of heparin-exposed patients. Its main clinical
complication is the development of thrombocytopenia with
or without thrombosis.581 In patients with AKI undergoing
CRRT, the diagnosis should therefore also be suspected in
patients with repeated premature filter clotting.630 The
likelihood of having HIT can be predicted by the so-called
4 T score, that includes the degree of thrombocytopenia, the
timing of onset of the fall in platelet count, the presence
of thrombosis or acute systemic symptoms, and the presence
of other etiologies of thrombocytopenia.631 If HIT is likely, all
heparins have to be stopped, including any ‘‘heparin lock’’
solutions for dialysis or other catheters.
With regard to the diagnosis and management of HIT,
we refer to the recent guideline of the ACCP581 and the
European best practice guideline on chronic dialysis.587 These
guidelines recommend the use of therapeutic doses of an
alternative nonheparin anticoagulant in patients with strong
suspicion of HIT. Candidates are the direct thrombin
inhibitors lepirudin, argatroban, or bivaluridin, or the anti-
thrombin-dependent Factor Xa inhibitors, danaparoid or
fondaparinix. Pharmacokinetic data and dosing guidelines
for these alternative anticoagulants have been published for
IHD588,632 and CRRT.633
Argatroban is a direct thrombin inhibitor, is eliminated
by the liver, has a short half-life, and can be monitored
with aPTT.634 A recent observational study on the use of
argatroban for anticoagulation during continuous dialysis in
30 patients with AKI and HIT derived a dosing equation,
based on illness severity scores or by use of indocyanine green
plasma clearance.635 Regional citrate anticoagulation has
been used along with reduced doses of argatroban or other
nonheparin anticoagulants in cases where bleeding occurs.
However, there are no published reports on this practice.
Pediatric considerations
Standardized protocols have been well established for both
heparin and regional citrate anticoagulation in children
receiving dialysis. The ppCRRT Registry Group has shown
that heparin- and citrate-based anticoagulation protocols
have been shown to confer equitable filter survival in
pediatric CRRT, and the use of either is clearly supported
over the use of no anticoagulation schemes.636 The main
advantage of citrate anticoagulation was the prevention of
systemic pharmacological anticoagulation of the patient,
which can be an issue in patients with multiorgan failure and
sepsis. Calcium is a requisite cofactor in both the intrinsic
and extrinsic coagulation cascades. Citrate functions by
binding free calcium, thereby inhibiting coagulation in both
the intrinsic and extrinsic coagulation pathways. The most
frequently studied pediatric citrate protocol636–638 uses
Anticoagulant Dextrose solution A (ACD-A, Baxter Health-
care, USA), prescribed based on the blood flow rate:
ACD rate ðml=hÞ ¼ blood pump rate ðml=minmin =hÞ1:5
ACD-A is infused via a stopcock at the catheter-CRRT
circuit connection leading to the CRRT machine. Since our
prescribed blood pump flow is 200ml/min, the resulting
ACD-A rate would be 300ml/h. The second aspect of the
citrate protocol provides prevention of citrate-induced
systemic hypocalcemia by providing a calcium chloride
continuous infusion (8 g calcium chloride per liter normal
saline) to the patient via a central line. The calcium chloride
rate is also based on the blood pump rate:
Calcium chloride ðml=hÞ¼ blood pump rate ðml=minmin =hÞ0:6
The goals of regional citrate anticoagulation are to
maintain the circuit ionized calcium between 0.8 and
1.6mg/dl (0.2 and 0.4mmol/l), and the patient’s systemic
ionized calcium in the normal physiologic range 4.4–5.2mg/
dl (1.1–1.3mmol/l). The circuit ionized calcium concentra-
tion is managed by adjustment of the citrate rate, while the
patient’s systemic ionized calcium concentration is managed
by adjustment of the calcium chloride rate.
RESEARCH RECOMMENDATIONS
K Randomized trials should compare unfractionated to
low-molecular-weight heparin during IHD in patients
with AKI.
K Randomized trials should compare unfractionated to
low-molecular-weight heparin during CRRT in patients
with AKI.
K Randomized trials should compare citrate to unfractio-
nated to low-molecular-weight heparin during CRRT in
patients with AKI.
K Future trials should compare a strategy without anti-
coagulation against one of anticoagulation during CRRT.
K Outcomes of interest for trials testing different anti-
coagulation strategies with RRT in AKI are clinical
end-points, including bleeding, renal recovery, mortality,
incidence of HIT, and surrogates such as circuit survival
and efficiency of dialysis, metabolic complications, and
effects on the coagulation system.
SUPPLEMENTARY MATERIAL
Supplementary Table 31: Evidence profile of RCTs examining the effect
of citrate vs. heparin/nadroparin in CRRT for AKI.
Supplementary Table 32: Summary table of RCTs examining the effect
of citrate vs. heparin/nadroparin in CRRT for AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 5.4: Vascular access for renal replacement
therapy in AKI
Functional vascular access is essential for adequate RRT. Basic
requirements are to ensure adequate and regular flow with
low morbidity. Most studies on indwelling tunneled dialysis
catheters have been performed in chronic dialysis patients.
For individuals requiring acute dialysis, the evidence on
dialysis catheters is more limited, but there is a body of
literature on nondialysis central venous catheters (CVC) in
intensive-care patients. Many of the recommendations for
patients requiring acute dialysis are, therefore, based on
extrapolation of evidence from tunneled dialysis catheters or
from nondialysis nontunneled CVC.
5.4.1: We suggest initiating RRT in patients with AKI via
an uncuffed nontunneled dialysis catheter, rather
than a tunneled catheter. (2D)
RATIONALE
Since most early catheter-related infections have a cutaneous
origin, tunneling the catheter under the skin together with a
subcutaneous anchoring system, may reduce the risk of
infection. Tunneling also increases mechanical stability of
the catheter. On the other hand, the insertion of a tunneled
cuffed catheter (TCC) is a cumbersome procedure that
requires expertise (mostly performed by surgeons or inter-
ventional radiologists), time, and effort (mostly performed in
the operating room or radiology department), thus poten-
tially delaying initiation of RRT. The removal of TCCs is also
technically more difficult.
A randomized trial compared the initial use of tunneled
vs. nontunneled femoral catheters in 34 patients with AKI.
Failure to insert the TCC occurred in four patients (12%)
that were excluded from the final analysis. In the remaining
30 patients, those with tunneled catheters had an increased
insertion time and more femoral hematomas, but also less
dysfunction, fewer infectious and thrombotic complications,
and a significantly better catheter survival.639 The small size
of this study and the absence of an intention-to-treat analysis
preclude firm conclusions (Suppl Table 33). In addition, the
use of tunneled catheters for starting acute dialysis is not
widespread practice.
Both the Centers for Disease Control (CDC) guidelines for
prevention of catheter-related infections and the KDOQI
guideline for vascular access in chronic dialysis patients
recommend using a cuffed catheter for dialysis if a prolonged
(e.g., 41–3 weeks) period of temporary access is antici-
pated.640,641 In two recent large randomized trials, the mean
duration of RRT for AKI was 12–13 days.562,563 This probably
does not justify the burden of an initial tunneled catheter in all
patients with AKI receiving RRT. Rather, selected use of tunneled
catheters in patients who require prolonged RRT is warranted.
No recommendation can be given regarding the optimal
timing to change the nontunneled-uncuffed catheter to a more
permanent access. It seems reasonable to create a more
permanent access when recovery of kidney function is unlikely.
The optimal timing should take into account the increased risk
of infection with untunneled catheters, but also the practical
issues related to the insertion of a tunneled catheter.
Several configurations of dialysis catheter lumen and tip
have emerged over the years with no proven advantage of one
design over another. The outer diameter varies between 11
and 14 French and it is self-evident that larger sizes decrease
the risk of inadequate blood flow. In order to provide an
adequate blood flow and reduce the risk of recirculation,
the tip of the catheter should be in a large vein (see
Recommendation 5.4.2). This means that the optimal length
is 12–15 cm for the right internal jugular vein, 15–20 cm for
the left internal jugular vein, and 19–24 cm for the femoral
vein.642–644
In PD, the Tenckhoff catheter, a soft, silicone rubber
catheter with a polyester cuff, reduced early complications such
as bowel perforation, massive bleeding, or leakage, and has
become the standard for PD. Further modifications, including
the use of swan-neck catheters, T-fluted catheters, curled
intraperitoneal portions, dual cuffs, and insertion through the
rectus muscle instead of the midline, have been made to reduce
remaining complications such as peritonitis, exit/tunnel
infection, cuff extrusion, obstruction, and dialysate leaks.645,646
Blind placement has been largely replaced by surgical
placement or placement guided by ultrasound/fluoroscopy,
laparoscopy, or peritoneoscopy.647–649 Continuous-flow PD
dictates the need for an efficient dual-lumen catheter or two
separate catheters with ports separated maximally.646 Outside
the pediatric setting, no investigations have specifically looked
at peritoneal catheters in the setting of AKI.
5.4.2: When choosing a vein for insertion of a dialysis
catheter in patients with AKI, consider these
preferences (Not Graded):
K First choice: right jugular vein;
K Second choice: femoral vein;
K Third choice: left jugular vein;
K Last choice: subclavian vein with preference for
the dominant side.
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RATIONALE
Although generally associated with the lowest rate of
infectious complications, the CDC guideline as well as the
KDOQI guideline recommend avoiding the subclavian vein
for RRT access,640,641 because this may lead to central vein
stenosis and jeopardize subsequent permanent access. This
recommendation is mainly derived from observational data
in ESRD patients showing a higher incidence of central vein
stenosis with subclavian than with jugular dialysis cathe-
ters.650,651 On the other hand, central vein stenosis has also
been described after jugular catheterization.652,653 Contact of
the catheter with the vessel wall is considered a primary
initiating event for catheter-related thrombosis and stenosis.
Catheters in the right internal jugular vein have a straight
course into the right brachiocephalic vein and superior vena
cava, and, therefore, the least contact with the vessel wall. A
catheter inserted through the subclavian or the left jugular
vein has one or more angulations. explaining the higher risk
of vessel contact and thrombosis/stenosis with subclavian
compared to jugular catheters,650,651 and with left-sided
compared to right-sided jugular catheters.654–656 The sub-
clavian vein should, therefore, be considered the last choice
for insertion of a dialysis catheter in patients with AKI,
especially when the risk of nonrecovery of kidney function is
substantial. Whether this recommendation should be ex-
tended to the left jugular vein remains unclear. In patients
where the subclavian vein remains the only available option,
preference should be given to the dominant side in order to
spare the nondominant side for eventual future permanent
access.
Because the subclavian vein should be avoided, the
remaining options are the jugular and femoral veins. The
use of femoral catheters is thought to be associated with the
highest risk of infection, and avoidance of femoral lines is
part of many ‘‘central line bundles’’ that intend to reduce the
incidence of catheter-related bloodstream infection.657
This dogma was questioned in a concealed, randomized,
multicenter, evaluator-blinded, parallel-group trial of 750
AKI patients, comparing the femoral with the jugular site for
first catheter insertion for RRT. Ultrasound was seldom used,
probably explaining the somewhat higher rate of failure on
one side and crossover in the jugular group. The rate of
hematoma formation was also higher in the jugular group.
In both groups, 20% of the catheters were antiseptic-
impregnated. Mean duration of catheterization was 6.2 days
for the femoral and 6.9 days for the jugular group. The major
reasons for catheter removal were death or ‘‘no longer
required’’. The incidence of catheter colonization at removal
(the primary end-point) was not significantly different
between the femoral and jugular group. When stratified
according to body mass index (BMI), those within the lowest
BMI tertile had a higher incidence of colonization with the
jugular site, whereas those within the highest BMI tertile had
the highest colonization rate with femoral catheters. Blood-
stream infection did not differ between the groups (2.3 per
1000 catheter-days for jugular and 1.5 per 1000 catheter-days
for femoral) but the study was not powered for this end-
point. This was also the case for thrombotic complications
(Suppl Table 34).658
Malfunction is another issue that needs to be considered
when choosing between a jugular and femoral vascular
access. Observational trials show more malfunctioning and a
shorter actuarial survival for femoral than for jugular dialysis
catheters],659–661 and more malfunction with left-sided
jugular catheters compared to right-sided.662 Recirculation
has been shown to be more frequent in femoral than
subclavian or jugular dialysis catheters, especially with
shorter femoral catheters.642,643 A secondary analysis of the
French multicenter trial did not find a difference in catheter
dysfunction between jugular and femoral catheters in the
intention-to-treat analysis. However, a separate analysis of
the right and left jugular catheters showed a trend toward
more dysfunction with femoral than with right jugular
catheters, but significantly more dysfunction with left jugular
compared to femoral catheters.663
Another point to consider is that any patient who has the
option of undergoing a kidney transplantation should not
have a femoral catheter placed to avoid stenosis of the iliac
vein, to which the transplanted kidney’s vein is anato-
mized.640 The presence of a femoral catheter also reduces the
patient’s mobilization, especially when the RRT is contin-
uous.
In summary, the right jugular vein appears to be the best
option for insertion of a dialysis catheter. Femoral catheters
are preferred over left jugular catheters because of reduced
malfunction, and the subclavian vein should only be
considered a rescue option. It is evident that individual
patient characteristics may require deviations from this order
of preferences. Catheter insertion should be performed with
strict adherence to infection-control policies, including
maximal sterile barrier precautions (mask, sterile gown,
sterile gloves, large sterile drapes) and chlorhexidine 2% skin
antisepsis.641,664,665
5.4.3: We recommend using ultrasound guidance for
dialysis catheter insertion. (1A)
RATIONALE
For several decades, techniques involving the use of anatomic
landmarks have been the traditional mainstay of accessing the
central venous system. Using the ‘‘blind’’ landmark technique
is not without significant morbidity and mortality. Compli-
cations of central venous catheterization include arterial
puncture (0.5–6%), hematoma (0.1–4.4%), hemothorax
(0.4–0.6%), pneumothorax (0.1–3.1%), and up to 10–20%
of insertion attempts are not successful.666,667 In view of their
large size, the risk of complications of dialysis catheters is
expected to be even higher. Two meta-analyses have
addressed the role of real-time two-dimensional ultrasound
for central vein cannulation, and concluded that, compared
to the landmark method, ultrasound-guided venous access
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increases the probability of successful catheter placement and
reduces the risk of complications, the need for multiple
catheter placement attempts, and the time required for the
procedure. The advantage appears most pronounced for the
jugular vein, whereas the evidence is scarce for the subclavian
and femoral vein.668,669 Subsequent large randomized trials
have confirmed the superiority of ultrasound guidance.670,671
Trials evaluating the placement of dialysis catheters in ESRD
patients, mostly with observational design, yield a similar
conclusion.672–678 The KDOQI guideline for vascular access
also recommends using ultrasound-assisted insertion.640
5.4.4: We recommend obtaining a chest radiograph
promptly after placement and before first use of an
internal jugular or subclavian dialysis catheter. (1B)
RATIONALE
Uncuffed, nontunneled dialysis catheters are semirigid. Their
tip should not be in the heart, because of the risk of atrial
perforation and pericardial tamponade. On the other hand, a
position too high in the brachiocephalic vein, especially with
subclavian and left-sided catheters, should also be avoided,
because it allows a narrow contact between the catheter tip
and the vessel wall, which may result in improper catheter
function and vessel thrombosis.655,679,680 The correct position
of the tip of a semirigid dialysis catheter is at the junction of
the superior vena cava and the right atrium, allowing the
catheter to run in parallel with the long axis of the superior
vena cava.679 Tunneled catheters are usually softer and can be
positioned into the right atrium, thus allowing a higher
blood flow.680
To confirm the correct position and to assess for potential
complications, a postprocedural chest radiograph is conven-
tionally performed. Although this procedure has been debated
after uneventful placement of a CVC, the high blood flows
used during RRT and the administration of anticoagulants
necessitate confirming the correct position before initiating
dialysis therapy.640 It should, however, be remembered that
none of the radiographic landmarks (carina, right tracheo-
bronchial angle, etc) that are used to exclude intra-atrial tip
position are 100% reliable.679,680 Echocardiography might be
another tool to confirm the correct position of the catheter.681
5.4.5: We suggest not using topical antibiotics over the
skin insertion site of a nontunneled dialysis cathe-
ter in ICU patients with AKI requiring RRT. (2C)
RATIONALE
The incidence of catheter-related bloodstream infection can
be reduced by implementing education-based programs and
so-called central-line bundles, that emphasize the importance
of hand hygiene, maximal barrier precautions upon inser-
tion, chlorhexidine skin antisepsis, optimal catheter site
selection, and daily review of line necessity.657 For detailed
instructions on catheter care, the reader is referred to pub-
lished guidelines.640,641,664,665 These guidelines also recom-
mend not using dialysis catheters for applications other than
RRT, except under emergency circumstances.641
A recent meta-analysis of five RCTs confirmed that topical
antibiotics (mainly mupirocin) reduce the risk of bacteremia,
exit-site infection, need for catheter removal, and hospitali-
zation for infection in ESRD patients.682 The majority of the
catheters in the included studies were tunneled. However, the
CDC, National Health Service, and Infectious Diseases
Society of America guidelines strongly recommend against
topical antibiotic ointment for the care of CVC, because of
their potential to promote fungal infections and antimicro-
bial resistance.641,664,665 For patients with AKI that are treated
in an ICU, it seems reasonable to follow this last recommen-
dation. No recommendations can be given for AKI patients
that are treated outside an ICU.
5.4.6: We suggest not using antibiotic locks for preven-
tion of catheter-related infections of nontunneled
dialysis catheters in AKI requiring RRT. (2C)
RATIONALE
Four meta-analyses have evaluated the efficacy of various
antibiotic lock solutions in chronic dialysis patients, and
conclude that they significantly reduce catheter-related
bloodstream infection. Drawbacks are the overall moderate
trial quality and the short follow-up that does not allow
excluding the development of resistance.682–685 However, the
CDC, National Health Service, and Infectious Diseases
Society of America guidelines strongly recommend against
routinely using antibiotic lock solutions in CVC, because of
their potential to promote fungal infections, antimicrobial
resistance, and systemic toxicity.641,664,665 Mentioned excep-
tions are long-term cuffed and tunneled catheters with
history of multiple catheter-related bloodstream infections
despite maximal adherence to aseptic technique,641,665
patients with limited venous access and history of recurrent
catheter-related bloodstream infection, or patients with
heightened risk of severe sequelae from a catheter-related
bloodstream infection.664
Pediatric considerations
Most of the guidelines for adults are applicable to children.
Functional CRRT circuit survival in children is favored by
larger catheter size686 that should be adapted to patient size
(Table 20).687 Recent data from the Prospective Pediatric
CRRT Registry group shows that internal jugular catheters
may be associated with longer functional CRRT circuit
survival, compared to femoral and subclavian access.686 In
addition, the Prospective Pediatric CRRT Registry group
showed extremely poor circuit survival with two single-
lumen 5 F catheters; these catheters should therefore be
avoided. Future permanent access in the form of an arterio-
venous graft or fistula for patients who develop CKD may be
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compromised if acute access is placed in a subclavian vein.
Clinicians must therefore consider the potential long-term
vascular needs of patients who may be expected to develop
CKD, especially children who have demonstrated excellent
long-term survival with CKD and ESRD.688
Analysis of a pediatric database (1989–1999) showed
that surgically placed Tenckhoff catheters for PD induce
less complications than more stiff percutaneously placed
catheters.689 A more recent retrospective analysis with
historical controls reports that, compared to the surgically
placed Tenckhoff catheter, using a more flexible catheter for
percutaneous insertion may achieve a comparable catheter
survival and complication rate.690
RESEARCH RECOMMENDATIONS
K Determine whether the initial use of a tunneled vs.
nontunneled catheter for RRT in AKI patients results in a
beneficial effect on catheter function and catheter-related
complications, including infections and number of
additional access procedures.
K Develop better means of predicting the need for long-
term access and better methods to select access site in
individual patients by balancing various risks and
benefits.
SUPPLEMENTARY MATERIAL
Supplementary Table 33: Summary table of RCTs examining the effect
of access placement with tunneled versus non-tunneled catheters on
AKI.
Supplementary Table 34: Summary table of RCTs examining the effect
of jugular vs. femoral access placement on AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
Table 20 | Catheter and patient sizes
Patient size Catheter size Site of insertion
Neonate Double-lumen 7F Femoral artery or
vein
3–6 kg Double- or triple-lumen 7F Jugular, subclavian,
or femoral
6–30 kg Double-lumen 8F Jugular, subclavian,
or femoral
415 kg Double-lumen 9F Jugular, subclavian,
or femoral
430 kg Double-lumen 10F or
triple-lumen 12F
Jugular, subclavian,
or femoral
Reprinted from Bunchman TE, Brophy PD, Goldstein SL. Technical considerations for
renal replacement therapy in children. Semin Nephrol 2008; 28: 488–492 687, copyright
2008, with permission from Elsevier; accessed http://www.seminarsinnephrology.org/
article/S0270-9295(08)00117-4/fulltext
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Chapter 5.5: Dialyzer membranes for renal
replacement therapy in AKI
Semipermeable hollow-fiber dialyzers are used as standard
of care for both solute clearance and ultrafiltration in
IHD and CRRT circuits. Membrane composition and
clearance characteristics vary among the commercially
available dialyzers. While no RCTs exist to provide definitive
recommendations for a particular dialyzer type, the charac-
teristics and potential side-effects of each dialyzer type
require consideration.
5.5.1: We suggest to use dialyzers with a biocompatible
membrane for IHD and CRRT in patients with
AKI. (2C)
RATIONALE
Semipermeable hollow-fiber dialyzers currently represent the
standard of care for IHD or CRRT for patients with AKI. All
dialyzer membranes induce some degree of activation of
blood components, a phenomenon called bioincompati-
bility.691 Earlier-generation dialyzer membranes composed of
cuprophane or unmodified cellulose were more bioincom-
patible and had the potential to cause a ‘‘dialyzer membrane
reaction’’, mediated by complement activation, release of
proinflammatory markers, and oxidative stress, and mani-
fested clinically by acute hypotension, vasodilatation, leuco-
penia, hypoxia and fever.692–697 More recently, modified
cellulosic membranes (with substitution of the hydroxyl
groups) and synthetic membranes composed of polyacyl-
nitrile, polysulfone, or poly(methyl methacrylate) have been
developed. These ‘‘biocompatible membranes’’ (or less
bioincompatible membranes) produce less complement and
cytokine activation, and decrease oxidative stress.697,698
Recent studies suggest that platelet activation might also
be involved in the bioincompatibility phenomenon.698–701
Another membrane characteristic that might have clinical
importance is the flux property, with membranes generally
being divided in low-flux and high-flux, the latter having
larger pores and thus the potential to clear larger solutes.
The question of whether membrane bioincompatibility or
flux has clinical relevance in the setting of AKI has been the
subject of many clinical trials. A recent meta-analysis of 10
randomized or quasi-randomized controlled trials in 1100
patients could not establish any advantage for biocompatible
or high-flux membranes.702 Of note, the authors chose to
include modified cellulose membranes in the bioincompa-
tible group, although other investigators consider modified
cellulosic membranes to be biocompatible. When comparing
the synthetic membranes to cuprophane, there was a trend
towards reduced mortality with the synthetic membranes.
This meta-analysis also did not assess the side-effects of
different membrane compositions on more proximal,
temporal associations, such as acute hypotension or fever.
As a result, we agree with the authors’ conclusion that the use
of either a biocompatible or modified cellulose acetate
membrane appears to be appropriate.
Recent observations reveal specific potential side-effects
when using certain dialyzer membranes. Bradykinin release
syndrome has been observed at the start of CRRT with
uncoated AN-69 membranes.703 Bradykinin release syn-
drome is characterized by acute hypotension and pulmonary
vascular congestion. The syndrome is usually self-limited and
is pH-dependent, and therefore more pronounced in patients
with severe acidosis. Also, priming of the circuit with banked
blood (that is acidotic and contains a large amount of citrate,
inducing hypocalcemia) may evoke bradykinin release
syndrome. Numerous measures have been published to
prevent or mitigate this syndrome, including zero-balance
HF to normalize the banked blood pH and calcium,704 or a
bypass maneuver in which the blood prime is given to the
patient instead of the circuit, while the patient is bled on to
the circuit with the saline prime discarded.705 Finally, a form
of bradykinin release syndrome has been reported in patients
receiving ACE-I and IHD with AN-69 membranes,706–708
since ACE-I prevent the conversion of bradykinin and
thereby prolong the hypotensive response when acidic blood
comes in contact with the AN-69 membrane. However,
others have disputed this interaction.704,705 Nevertheless,
clinicians should be aware of the potential for bradykinin
release syndrome if an uncoated AN-69 membrane is
employed for RRT, especially in acidotic patients or in those
receiving ACE-I. Neutralizing the electronegativity of the
AN-69 membrane by coating with polyethyleneimine sig-
nificantly reduces bradykinin generation.709
Whether conventional dialysis membranes are able to
affect clinical outcomes in sepsis by removal of inflammatory
mediators remains highly controversial. Until further evi-
dence becomes available, the use of RRT to treat sepsis should
be considered experimental.
RESEARCH RECOMMENDATIONS
K Future research should assess the impact of middle-
molecule clearance by high-flux membranes and/or
membrane adsorption on patient outcome in sepsis.
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The comparator group should be patients with sepsis that
do not receive extracorporeal treatment (if no AKI) or
conventional RRT (if AKI).
K The potential impact of dialyzer membrane composition
(material, flux, etc.) on outcomes in patients with AKI
remains unsettled, due to the relatively small size of trials.
It would be useful to conduct larger trials comparing
different membranes and examining patient-centered
outcomes include survival, renal recovery, and resource
utilization.
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Chapter 5.6: Modality of renal replacement therapy
for patients with AKI
Controversy exists as to which is the optimal RRT modality
for patients with AKI. In current clinical practice, the
choice of the initial modality for RRT is primarily based
on the availability of, and experience with, a specific
treatment and on the patient’s hemodynamic status. Transi-
tions between CRRT and IHD are also frequent, mostly
determined by the hemodynamic status of the patient or
coagulation problems. Experience with PD in AKI is limited,
except in the pediatric setting and in regions with limited
resources.
5.6.1: Use continuous and intermittent RRT as comple-
mentary therapies in AKI patients. (Not Graded)
RATIONALE
Current modalities of RRT for AKI include IHD, CRRT, and
PD. An overview of the different modalities of RRT and their
commonly used settings is given in Table 21.
Since the introduction of CRRT into clinical practice in
the early 1980 s, its use in critically ill patients with AKI has
increased steadily.710–712 The theoretical advantages of CRRT
over IHD are the slower fluid removal, resulting in more
hemodynamic stability and better control of fluid balance,
the slower control of solute concentration, avoiding large
fluctuations and fluid shifts (including a reduced risk
[worsening] of cerebral edema), the great flexibility (allowing
adaptation of the treatment to the patient’s need at any time),
and the ability to perform the treatment with relatively
simple and user-friendly machines (allowing ICU nurses to
monitor the treatment). Disadvantages include the need for
immobilization, the use of continuous anticoagulation, the
risk of hypothermia and, in some settings, higher costs.
Major advantages of IHD over CRRT are the fast removal
of toxins and the restricted treatment period, allowing
down-time for diagnostic and therapeutic interventions.
IHD may, therefore, be the preferred treatment in patients
where immediate removal of small solutes is required, such as
severe hyperkalemia, some cases of poisoning, and tumor
lysis syndrome. Hybrid treatments, such as SLED, may share
some of the advantages of both IHD and CRRT without
having their disadvantages (Table 22).
Several RCTs have compared CRRT to IHD in AKI
patients. The most inclusive meta-analysis was performed by
the Cochrane Collaboration, analyzing 15 RCTs in 1550 AKI
patients. This analysis concluded that outcomes were similar
in critically ill AKI patients treated with CRRT and IHD for
hospital mortality (RR 1.01; 95% CI 0.92–1.12; n¼ 1245),
ICU mortality (RR 1.06; 95% CI 0.90–1.26; n¼ 515), length
of hospitalization (mean deviation 6.1; 95% CI 26.45
to 14.25; n¼ 25), and renal recovery (free of dialysis on
discharge) in survivors (RR 0.99; 95% CI 0.92–1.07;
n¼ 161).713 Comparable results have been reported by other
meta-analyses.714,715 Individual studies used different defini-
tions of AKI and were underpowered. Most of the trials
excluded patients with hypotension or maximized efforts to
improve the hemodynamic tolerance of IHD. The high rate of
crossover between the treatment modalities also complicates
the interpretation of the results. In addition, in some of the
trials, IHD patients were treated with bioincompatible
membranes and studies were not standardized for treatment
dose. A subsequent RCT not included in the Cochrane meta-
analyses reported similar outcomes.716 Two recent studies,
confined to single geographic regions, showed reduced costs
with IHD compared to CRRT.717,718 However, an analysis of
cost ranges from a multicenter, multinational observational
study found considerable heterogeneity in costs related to
IHD and CRRT, and concluded that either therapy might be
Table 21 | Typical setting of different RRT modalities for AKI (for 70-kg patient)
SCUF CVVH CVVHD CVVHDF PD SLED IHD
Blood flow (ml/min) 100–200 150–250 150–250 150–250 N/A 100–300 200–300
Predominant solute transport
principle
convection convection diffusion diffusionþ convection diffusion diffusion diffusion
Ultrafiltrate (ml/h) 100–300 1500–2000 variable 1000–1500 variable variable variable
Dialysate flow (ml/h) 0 0 1500–2000 1000–1500 1–2 l per exchange 100–300ml/min 300–500ml/min
Effluent volume (l/d) 2–8 36–48 36–48 36–72 24–48 N/A N/A
Replacement fluid for zero
balance (ml/h)
0 1500–2000 0 1000–1500 0 0 0
Urea clearance (ml/min) 1–5 25–33 25–33 25–33 variable 80–90 variable
CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemodialysis, CVVHDF, continuous venovenous hemodialfiltration; IHD, intermittent
hemodialysis; N/A, not applicable; PD, peritoneal dialysis; SCUF, slow continuous ultrafiltration; SLED, slow low-efficiency dialysis.
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more or less costly depending on local practices, especially
staffing.719
Some large observational studies, including all patients
receiving RRT, suggest that CRRT is an independent predic-
tor of renal recovery among survivors.720–722 This evidence,
however, is insufficient to fully elucidate the impact of choice
of therapy on this outcome. Appropriately planned prospec-
tive trials will be required to address this issue.
In conclusion, no RRT is ideal for all patients with AKI.
Clinicians should be aware of the pros and cons of different
RRTs, and tailor RRT on the basis of the individual and
potentially changing needs of their patients. Besides the
individual patient’s characteristics, the available expertise and
resources may also be an important determinant of the
ultimate choice.
5.6.2: We suggest using CRRT, rather than standard
intermittent RRT, for hemodynamically unstable
patients. (2B)
RATIONALE
Many clinicians prefer CRRT in critically ill AKI patients with
severe hemodynamic instability, because of better hemo-
dynamic tolerance due to the slower fluid removal and
the absence of fluid shifts induced by rapid solute removal.
The Cochrane meta-analysis could not establish a difference
in the number of patients with (however poorly defined)
hemodynamic instability (RR 0.48; 95% CI 0.10–2.28;
n¼ 205) nor with (variably defined) hypotension (RR 0.92;
95% CI 0.72–1.16; n¼ 514). On the other hand, the mean
arterial pressure at the end of the treatment was significantly
higher with CRRT than with IHD (mean deviation 5.35; 95%
CI 1.41–9.29; n¼ 112) and the number of patients requiring
escalation of vasopressor therapy was significantly lower
with CRRT compared to IHD (RR 0.49; 95% CI 0.27–0.87;
n¼ 149).713 In general, the number of patients included in
these analyses of the hemodynamic tolerance of RRT remains
limited, and none of the RCTs has specifically looked at the
effect of different modalities of RRT in patients with shock.
SLED has been proposed as an alternative to other forms
of RRT and is used in many centers worldwide for logistical
reasons. A recent review723 summarizes the results obtained
with SLED in several studies and discusses in detail the
technical aspects of this dialysis method. However, rando-
mized trials comparing IHD with SLED have not been
performed. Also, clinical experience is far more limited with
SLED compared to CRRT, and very few randomized studies
have compared SLED to CRRT. A first small trial in 39 AKI
patients did not find any difference in hemodynamics, and
less need for anticoagulation with SLED compared to
CRRT.724 An (even smaller) Australian study showed similar
control of urea, creatinine, and electrolytes, but a better
control of acidosis and less hypotension during the first
hours of the treatment with CRRT.725,726 A recent retro-
spective analysis examined the mortality data from three
general ICUs in different countries that have switched their
predominant therapeutic dialysis approach from CRRT to
SLED. This change was not associated with a change in
mortality.727 In addition, Fieghen et al.728 examined the
Table 22 | Theoretical advantages and disadvantages of CRRT, IHD, SLED, and PD
Modality Potential setting in AKI Advantages Disadvantages
IHD Hemodynamically stable Rapid removal of toxins and low-molecular-weight
substances
Allows for ‘‘down time’’ for diagnostic and
therapeutic procedures
Reduced exposure to anticoagulation
Lower costs than CRRT
Hypotension with rapid fluid removal
Dialysis disequilibrium with risk of cerebral
edema
Technically more complex and demanding
CRRT Hemodynamically unstable
Patients at risk of increased
intracranial pressure
Continuous removal of toxins
Hemodynamic stability
Easy control of fluid balance
No treatment-induced increase of intracranial
pressure
User-friendly machines
Slower clearance of toxins
Need for prolonged anticoagulation
Patient immobilization
Hypothermia
Increased costs
SLED Hemodynamically unstable Slower volume and solute removal
Hemodynamic stability
Allows for ‘‘down time’’ for diagnostic and
therapeutic procedures
Reduced exposure to anticoagulation
Slower clearance of toxins
Technically more complex and demanding
PD Hemodynamically unstable
Coagulopathy
Difficult access
Patients at risk of increased
intracranial pressure
Under-resourced region
Technically simple
Hemodynamic stability
No anticoagulation
No need for vascular access
Lower cost
Gradual removal of toxins
Poor clearance in hypercatabolic patients
Protein loss
No control of rate of fluid removal
Risk of peritonitis
Hyperglycemia
Requires intact peritoneal cavity
Impairs diaphragmatic movement, potential
for respiratory problems
CRRT, continuous renal replacement therapy; IHD, intermittent hemodialysis; PD, peritoneal dialysis; SLED, sustained low-efficiency dialysis.
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relative hemodynamic tolerability of SLED and CRRT in
critically ill patients with AKI. This study also compared the
feasibility of SLED administration with that of CRRT and
IHD. Relatively small cohorts of critically ill AKI patients in
four critical-care units included 30 patients treated with
CRRT, 13 patients with SLED, and 34 patients with IHD.
Hemodynamic instability occurred during 22 (56.4%) SLED
and 43 (50.0%) CRRT sessions (P¼ 0.51). In a multivariable
analysis that accounted for clustering of multiple sessions
within the same patient, the OR for hemodynamic instability
with SLED was 1.20 (95% CI 0.58–2.47) compared to CRRT.
Significant session interruptions occurred in 16 (16.3%),
30 (34.9%), and 11 (28.2%) of IHD, CRRT, and SLED
therapies, respectively. This study concluded that, in critically
ill patients with AKI, the administration of SLED is feasible
and provides hemodynamic control comparable to CRRT.
In conclusion, in the presence of hemodynamic instability
in patients with AKI, CRRT is preferable to standard IHD.
SLED may also be tolerated in hemodynamically unstable
patients with AKI in settings where other forms of CRRT are
not available, but data on comparative efficacy and harm are
limited. Once hemodynamic stability is achieved, treatment
may be switched to standard IHD.
5.6.3: We suggest using CRRT, rather than intermittent
RRT, for AKI patients with acute brain injury or
other causes of increased intracranial pressure or
generalized brain edema. (2B)
RATIONALE
In a patient with acute brain injury, IHD may worsen
neurological status by compromising cerebral perfusion
pressure. This may be the result of a decrease of mean
arterial pressure (dialysis-induced hypotension) or an
increase of cerebral edema and intracranial pressure (dialysis
disequilibrium), and may jeopardize the potential for
neurologic recovery. Dialysis disequilibrium results from
the rapid removal of solutes, resulting in intracellular fluid
shifts. Both hypotension and disequilibrium can be avoided
by the slow progressive removal of fluids and solutes that
occurs during CRRT.729 Small observational trials and case
reports in patients with intracranial pressure monitoring
indeed reported increases in intracranial pressure with
IHD.730,731 Using CT scans to measure brain density, Ronco
et al.732 showed an increase of brain water content after IHD,
whereas no such changes were observed after CRRT.
Protocols for decreasing hemodynamic instability with
intermittent RRT
Intradialytic hypotension is a major problem during RRT in
AKI patients, limiting its efficacy and causing morbidity.
Surprisingly, there are only a few studies assessing this highly
relevant clinical problem. Paganini et al.733 performed a
small-sample (10 subjects) randomized crossover controlled
trial in AKI patients. They evaluated two different RRT
protocols: fixed dialysate sodium (140 mEq) and fixed ultra-
filtration rate vs. variable dialysate sodium (160 to 140 mEq)
and variable ultrafiltration rate (50% in first third of the
treatment and 50% in the last two-thirds of the treatment).
The variable sodium and ultrafiltration rate protocol
achieved better hemodynamic stability, needed fewer inter-
ventions, and induced lesser relative blood volume changes,
despite higher ultrafiltration rates.
Schortgen et al.734 evaluated the effects of implementing
specific guidelines aiming to improve IHD hemodynamic
tolerance. The clinical practice algorithm included priming
the dialysis circuit with isotonic saline, setting dialysate
sodium concentration at 145 mEq/l, discontinuing vasodi-
lator therapy, and setting dialysate temperature to below
37 1C. A total of 289 RRT sessions were performed in 76
patients and compared to a historical series of 248 sessions in
45 patients. Hemodynamic tolerance was better in the
guideline patients. They developed less systolic drop at and
during RRT. They also had less hypotensive episodes and the
need for therapeutic interventions was less frequent. The
adoption of guidelines did not influence ICU mortality, but
death rate was significantly lower than predicted from illness
severity in the guideline patients, but not in the historical
series subjects. Length of ICU stay was also reduced for
survivors in the protocol-oriented group, as compared to the
historical series of patients.
Peritoneal dialysis
In the developing world, the development of CRRT
techniques has resulted in a substantial decline in the
expertise with, and use of, PD for treatment of AKI. The
use of PD in AKI is mainly confined to pediatrics and in
regions with limited resources, because of its ease of use, low
cost, and minimal requirements on infrastructure. Other
advantages include the lack of a need for vascular access and
anticoagulation, the absence of a disequilibrium syndrome
and the relatively good hemodynamic tolerance compared to
IHD. Disadvantages are the overall lower effectiveness
(especially in patients with splanchnic hypoperfusion or
who are on vasopressors), the risk of protein loss, the
unpredictability of solute and fluid removal, the need for an
intact peritoneal cavity, risk of peritonitis, diaphragmatic
splinting leading to ventilatory compromise and fluctuating
blood glucose levels. Recent developments in the technique of
PD (use of flexible and cuffed catheters, automatic cycling,
and continuous flow PD) have increased its potential to
become an acceptable alternative to other forms of RRT in
AKI,735–737 but direct comparative effectiveness trials are
extremely limited. Earlier reports on PD in AKI are mainly
uncontrolled observations. Only two relatively recent rando-
mized trials have compared PD to other modalities of RRT in
AKI. Phu randomized 70 patients with septic AKI to PD or
continuous venovenous hemofiltration (CVVH) and found
a better survival with CVVH. However, the PD treat-
ment appeared not to be ‘‘up to date’’ with use of a rigid
catheter, manual exchanges with open drainage and acetate
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buffering.738 The second trial compared daily IHD to high-
volume PD (with Tenckhoff catheter and automated cycler)
and showed no difference in survival or recovery of kidney
function. The duration of RRTwas significantly shorter in the
PD group (Suppl Table 35).739 However, this trial has not
been published in a peer-reviewed journal and the randomi-
zation process is unclear. Currently indications for PD in
patients with AKI may include bleeding diathesis, hemo-
dynamic instability and difficulty in obtaining a vascular
access. Extremely high catabolism, severe respiratory failure,
severe ileus, intra-abdominal hypertension, recent abdominal
surgery and diaphragmatic peritoneum-pleura connections
are contraindications to PD.
Pediatric considerations
RRTmodality choice for children with AKI is guided by many
of the same principles used for adult patients. However, since
severe AKI is relatively rare in children compared to adults,
occurring in less than 1% of hospitalized children740 and only
4.5% of children admitted to an intensive care unit,741 the
impact of local expertise and resource restrictions may be
greater for pediatric acute RRT modality decisions. As noted
below, each modality of acute RRT can be successfully
provided to pediatric patients of all sizes. Thus, with rare
exception driven by medical indication or contraindication,
no form of acute RRT can be recommended above another at
the present time. Each program should evaluate which
modality is provided most optimally and feasibly in its
particular setting.
Provision of RRT as IHD, PD, or CRRT is now a mainstay
of treatment for the child with severe AKI. The widely
varying size range of pediatric patients imparts technical
considerations in selection of a modality. Given their small
size and associated low blood volume, PD may provide the
least technically challenging option for infants and small
children. However, technological advances aimed at provid-
ing accurate ultrafiltration with volumetric control incorpo-
rated into IHD and CRRT equipment, and disposable lines,
circuits, and dialyzers sized for the entire pediatric weight
spectrum have made IHD and CRRT safer and feasible for
children of all ages and sizes.570,742–744 Transition from the
use of adaptive CRRT equipment to production of high-flow
machines with volumetric control allowing for accurate
ultrafiltration flows has likewise lead to a change in pediatric
RRT modality prevalence patterns in the USA. Accurate
ultrafiltration and blood flow rates are crucial for pediatric
RRT, since the extracorporeal circuit volume can comprise
more than 15% of a small pediatric patient’s total blood
volume, and small ultrafiltration inaccuracies may represent a
large percentage of a small pediatric patient’s total body
water. Polls of USA pediatric nephrologists demonstrate
increased CRRT use over PD as the preferred modality for
treating pediatric ARF. In 1995, 45% of pediatric centers
ranked PD and 18% ranked CRRT as the most common
modality used for initial ARF treatment. In 1999, 31% of
centers chose PD vs. 36% of centers reported CRRT as their
primary initial modality for ARF treatment.745
In the 1990 s, survival rates stratified by RRT modality were
better for children receiving IHD (73–89%) than those receiving
PD (49–64%) or CRRT (34–42%).545,746 However, this analysis
did not correct for illness severity. More recent data demon-
strate much improved survival in children receiving
CRRT,543,544,546,570 with survival rates ranging from 50–70%
for children with multiple-organ dysfunction who receive
CRRT. While no RCT exists to assess the impact of CRRT
modality on survival, convective modalities were associated with
increased survival in children with stem-cell transplants in a
prospective cohort study (59% vs. 27%, Po0.05).747
RESEARCH RECOMMENDATIONS
K Large RCTs should compare SLED against other forms of
RRT in patients with AKI. These trials should be
standardized for treatment dose, buffer, membrane,
anticoagulant, and timing of treatment.
K The effects of different modalities of RRT on the long-
term need for chronic dialysis, along with mortality,
should be evaluated in prospective randomized trials.
SUPPLEMENTARY MATERIAL
Supplementary Table 35: Summary table of RCTs examining the effect
of dialysis modality (continuous vs. intermittent RRT) in AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 5.7: Buffer solutions for renal replacement
therapy in patients with AKI
One goal of CRRT is to maintain normal or near-normal
acid-base balance, thus preventing detrimental effects of
acidosis on cardiovascular performance and hormonal
response. Options for correction of metabolic acidosis
include the use of acetate-, lactate-, and bicarbonate-
containing replacement solutions or dialysate. Some centers
use citrate anticoagulation, and the citrate load provides an
adequate supply of anionic base to control metabolic
acidosis. Dialysate solutions for IHD are produced on-line
by the dialysis machine, by mixing specially treated
municipal water with electrolytes. Dialysate or replacement
solutions for CRRT are produced commercially or locally in
hospital pharmacies.
5.7.1: We suggest using bicarbonate, rather than lactate,
as a buffer in dialysate and replacement fluid for
RRT in patients with AKI. (2C)
5.7.2: We recommend using bicarbonate, rather than
lactate, as a buffer in dialysate and replacement
fluid for RRT in patients with AKI and circulatory
shock. (1B)
5.7.3: We suggest using bicarbonate, rather than lactate,
as a buffer in dialysate and replacement fluid for
RRT in patients with AKI and liver failure and/or
lactic acidemia. (2B)
RATIONALE
Options for correction of metabolic acidosis in patients with
AKI include acetate, lactate, bicarbonate, and citrate. The use
of acetate has been largely abandoned in view of the
associated hemodynamic instability and weight loss, probably
related to excessive nitric oxide production and cytokine
synthesis.748 Citrate, used for regional anticoagulation of the
extracorporeal circuit, is alkalinizing, and most patients
receiving citrate anticoagulation do not need an additional
buffer in the dialysate or replacement fluid.
Original HF solutions contained lactate as a buffer. Under
normal circumstances, this lactate is metabolized, resulting in
adequate correction of acidosis in most patients. A survey in
34 Australian ICUs concluded that 55% of the ICU patients
with AKI were treated with lactate-based solutions710 that, in
most countries, are less expensive than bicarbonate solutions.
In addition, bicarbonate solutions have a higher risk of
bacterial contamination and the solution is unstable in the
presence of calcium and magnesium. However, in recent
years, bicarbonate has gained popularity because of concerns
that lactate may not be rapidly metabolized in the setting of
multiple-organ failure.749 Since lactate is a strong anion,
insufficient lactate conversion will result in worsening
acidosis, especially since bicarbonate losses are ongoing in
the extracorporeal circuit. Hyperlactatemia has also been
linked to impaired cellular function and catabolism due to
lowering of the cellular redox state and phosphorylation
potential.750 In addition, iatrogenic increases in lactate levels
may lead to misinterpretation of the clinical situation. The
risk of ‘‘lactate intolerance’’ is highest in patients with liver
failure (impaired lactate clearance) or circulatory shock
(increased endogenous lactate production).
Few adequately designed trials have compared different
buffers during RRT in AKI patients, and most of them have
been performed during CRRT. Barenbrock et al.751 rando-
mized 117 AKI patients to CVVH with lactate or bicarbonate
replacement fluid. The use of bicarbonate resulted in better
correction of acidosis and lower lactate levels. Also, the
incidence of hypotension and other cardiovascular events was
lower with bicarbonate. In the subgroup of patients with
cardiac failure, mortality tended to be lower with bicarbo-
nate, whereas in the subgroup of septic patents no difference
in outcome was found (Suppl Table 36). A nonrandomized
crossover study in 54 patients with multiple-organ dysfunc-
tion undergoing CVVHDF confirmed the superior control of
acidosis and better hemodynamic tolerance with bicarbo-
nate.752 However, another RCT in 40 patients treated with
CVVH could not find a difference in hemodynamic
tolerance, despite the higher lactate levels in the lactate-
buffered group.753 Differences in the case-mix may explain
these different results.
Two small prospective randomized crossover comparisons
of bicarbonate- and lactate-buffered solutions in AKI patients
treated with CVVH or CVVHDF found elevated serum
lactate levels with lactate, an effect that was more pronounced
in patients with hepatic insufficiency.754,755 An observational
trial in 27 patients found a compromised lactate tolerance in
patients with coincidental liver disease, those on inotropic
support, and in patients with initial blood lactate measure-
ments of 490.1mg/dl (410mmol/l) and large base
deficits.756
In conclusion, the use of bicarbonate as a buffer in the
dialysate or replacement fluid of AKI patients results in better
correction of acidosis, lower lactate levels, and improved
hemodynamic tolerance. This effect is most pronounced in
patients with circulatory problems and in those with liver
dysfunction.
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5.7.4: We recommend that dialysis fluids and replacement
fluids in patients with AKI, at a minimum, comply
with American Association of Medical Instrumen-
tation (AAMI) standards regarding contamination
with bacteria and endotoxins. (1B)
RATIONALE
Replacement fluids for HF or HDF are infused directly into
the patient’s circulation and should be sterile. A potential
major step forward in acute RRT, reducing the costs and the
need for storage of fluids, is the on-line production of
replacement fluids, which is achieved by passing water and/or
dialysate through two or three ultrafilters before being
infused.757,758 On-line production of replacement fluids has
not yet been approved by the FDA or by some regulatory
authorities in Europe.
Conventional IHD uses nonsterile dialysate, as there is no
direct contact between blood and dialysate. However, with the
use of high-permeability membranes, the lower blood side
pressures at the end of the dialyzer filter may allow back-
filtration of dialysate to the blood,759 raising the possibility of
endotoxin or other contaminant exposure. Two studies
confirmed microbial contamination of (locally prepared and
commercial) fluids and circuitry during CRRT.760,761 Dialysate
for CRRT should preferably be ultrapure, and should at least
comply with quality standards for dialysis water and dialysis
fluids that may differ worldwide (Table 23).762
Finally, an international quality standard for dialysis fluid
is in preparation by the International Society for Standardi-
zation. Until international standards are in place, we
recommend that dialysis fluids and replacement fluids in
patients with AKI, at a minimum, comply with AAMI
standards for bacteria and endotoxins. When local standards
exceed AAMI standards, local standards should be followed
(Table 23).
RESEARCH RECOMMENDATION
K Further studies are required to explore the impact of on-
line preparation of replacement fluid for HDF on clinical
outcomes (incidence of sepsis, renal recovery, mortality)
in AKI patients requiring RRT.
SUPPLEMENTARY MATERIAL
Supplementary Table 36: Summary table of RCTs examining the effect
of bicarbonate vs. lactate as buffer for CVVH replacement fluid on
acidosis in AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
Table 23 |Microbiological quality standards of different regulatory agencies
ANSI/AAMI/ISO763–765 ERA-EDTA guidelines765a
Water for dialysis
Bacteria (CFU/ml) o100 (action level at 50) o100
Endotoxin (EU/ml) o0.5 o0.25
Dialysate
Bacteria (CFU/ml) o100 (action level at 50) o100
Endotoxin (EU/ml) o0.5 o0.25
Ultrapure dialysate
Bacteria (CFU/ml) o0.1 o0.1
Endotoxin (EU/ml) o0.03 o0.03
Substitution fluid for infusion
Bacteria (CFU/ml) Sterile o106
Endotoxin (EU/ml) Undetectable o0.03
AAMI, Association for the Advancement of Medical Instrumentation; ANSI, American National Standards Institute; CFU, colony-forming units; ERA-EDTA, European Renal
Association—European Dialysis and Transplant Asssociation; EU, endotoxin units; ISO, International Organization for Standardization.
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Chapter 5.8: Dose of renal replacement therapy in AKI
The first report of RRT in AKI was published in 1965.766
Despite more than six decades of clinical experience and
research, controversy remains about the best way to measure
and what constitutes optimal dose of RRT for patients with
AKI. Indeed, three of the top five questions considered most
relevant by an international expert’s panel on RRT delivery in
AKI were about dose.767
The methods used for RRT dose quantification in AKI
have several limitations, and have not been fully validated in
this specific population. Earlier single-center trials assessing
the effects of RRT dose in AKI provided conflicting
results.531,768–772 Considering the complexity of AKI patients,
RRT dose, by itself, may have less impact on mortality both
in patients with very high or very low chance of surviving,
but may be most important in patients with intermediate
scores of disease severity.773 In addition, it is possible that
dose and timing are closely linked factors, i.e., a high RRT
dose may not work adequately if provided late, or an early
RRT starting may not be able to change outcomes if the dose
is not optimized. Currently, only one small RCT considered
both variables at the same time.531
5.8.1: The dose of RRT to be delivered should be
prescribed before starting each session of RRT.
(Not Graded) We recommend frequent assessment
of the actual delivered dose in order to adjust the
prescription. (1B)
5.8.2: Provide RRT to achieve the goals of electrolyte,
acid-base, solute, and fluid balance that will meet
the patient’s needs. (Not Graded)
RATIONALE
The judgment and awareness of how much of a particular
therapeutic procedure should be, and actually it is, delivered
is essential for a good medical practice. However, recent
surveys have shown a disappointingly low number of
physicians that report being aware of, or calculating, RRT
dose in AKI.774
Although widely used for evaluation of RRT in CKD, Kt/V
urea has important limitations as a tool for RRT dosing in
AKI. AKI patients are metabolically unstable, with variations
in urea generation. In addition, their urea volume of
distribution appears to exceed the patient’s total body-water
volume.775 Different ways to measure Kt/V obtained
significantly different results in AKI patients.776 In the same
way, the selection of a target serum urea level as an indicator
of dialysis dose is highly arbitrary, as serum urea is influenced
by several extrarenal factors, such as ethnicity, age, gender,
nutrition, presence of liver disease, sepsis, muscle injury,
drugs, etc.
Several clinical investigations have shown that the actual
delivered dose of RRT in AKI patients is frequently smaller
than the prescribed dose, and even smaller than the
recommended minimum for CKD patients.771,773,776–778
Impediments to adequate dose delivery were hemodynamic
instability, patient size, access problems, technical problems,
need for patient transportation, and early filter clotting.
Trials studying dose in CRRT have used the amount
of effluent volume normalized by the patient’s weight
and procedure time as a parameter for dose evaluation.
However, the actual effluent flow will be influenced by
interruptions of CRRT, and effluent flow will exceed actual
dose with use of predilution or with reductions in mem-
brane permeability during the treatment. In summary, it is
essential to check very carefully if the prescribed RRT dose
is really being delivered to AKI patients. Increasing filter
size, dialysis time, blood flow rate, dialysate flow rate, and/or
effluent flow rate should be considered in case of dose
inadequacy.
In determining a prescription of RRT it is mandatory to
consider parameters other than small-solute clearance, such
as patients’ fluid balance, acid-base and electrolyte home-
ostasis, and nutrition, among others, as possible components
of an optimal RRT dose. In fact, positive fluid balance
appears to be an independent risk factor for mortality in AKI
patients.83
5.8.3: We recommend delivering a Kt/V of 3.9 per week
when using intermittent or extended RRT in
AKI. (1A)
5.8.4: We recommend delivering an effluent volume of
20–25ml/kg/h for CRRT in AKI (1A). This will
usually require a higher prescription of effluent
volume. (Not Graded)
RATIONALE
Three RCTs evaluated the dose of IHD in AKI (Suppl Tables
37 and 38). Schiffl et al.771 compared daily to alternate-day
IHD in 146 ICU patients with AKI. RRT was started with
rather high values of SCr (over 4.5mg/dl [398 mmol/l]) and
BUN (around 90mg/dl [32.1mmol/l urea]). The daily arm
received a weekly Kt/V approximately two times higher than
the alternate-day arm (5.8 ± 0.6 vs. 3 ± 0.6, respectively).
Daily IHD resulted in lower mortality (28% vs. 46%,
P¼ 0.01) and faster recovery of kidney function (9 ± 2 vs.
16± 6 days, P¼ 0.001). Major limitations of this study were
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inadequate randomization, a ‘‘very low dose’’ in the control
group (actually less than that recommended for CKD). Also
overall mortality in the study (34%) was lower than in other
studies in this population, suggesting that the results may not
generalize. Moreover, alternate-day IHD was associated with
significant differences in fluid removal and dialysis-associated
hypotension, suggesting that aspects other than solute
control might modify patient outcomes.
The Veterans Affairs/National Institutes of Health Acute
Renal Failure Trial Network (ARFTN) study563 was a RCT
assessing the effects of intensive compared to less-intensive
RRT in 1124 ICU patients with AKI in 27 Veterans Affairs–
and university-affiliated North-American centers. Within
each randomization arm patients were switched between
IHD and CRRT or SLED, based on their hemodynamic
status, reflecting average clinical practice in the USA.
Intermittent treatments were prescribed at a Kt/V of 1.4,
with a delivered Kt/V averaging 1.3, and were performed
three (less-intensive arm) or six (more-intensive arm) times
per week. Consequently, the weekly Kt/V was approximately
6.5 in the intensive and 3.9 in the less-intensive arm.
Mortality at 60 days was similar in both groups (53.6% and
51.5%) as was the percentage of patients recovering kidney
function (15.4% and 18.4%). Limitations of this study
include the predominance of males, and the nonstandardized
timing for initiating RRT. In addition, a significantly higher
frequency of hypotension and electrolyte disturbances were
seen in the more-intensive arm. Similar to what has been
reported in chronic dialysis, acute IHD results in under-
dosing when Kt/V is not measured. In the ARFTN study, the
first session of IHD had an average delivery of 1.1 Kt/V, while
the prescribed dose was 1.4.
The Hannover Dialysis Outcome Study768 randomized
148 ICU patients with AKI to two different doses of SLED: a
standard-dialysis arm dosed to maintain plasma urea levels
between 120–150mg/dl (20–25mmol/l), or an intensified-
dialysis arm dosed to maintain plasma urea levelso90mg/dl
(o15mmol/l). Patients were included with SCr around
3mg/dl (265 mmol/l) and plasma urea around 60mg/dl
(10mmol/l). The mean plasma urea was kept at 68 ±
24mg/dl (11.3 ± 4mmol/l) in the intensified and 114 ±
36mg/dl (19 ± 6mmol/l) in the standard group. Mortality
at 28 days was not statistically different between groups
(38.7% and 44.4%) and the frequency of survivors recovering
kidney function at day 28 was very similar (63% and 60%).
In CKD, the analysis by Gotch and Sargent779 of the
National Cooperative Dialysis Study showed that survival
could be increased by increasing Kt/V to 1.0–1.2. Analysis of a
large database of 2311 Medicare IHD patients also showed a
strong association between the delivered IHD dose and
mortality, with a decreased mortality risk of 7% for each 0.1
higher level of delivered Kt/V in CKD patients. However,
above a Kt/V of 1.3, no further decrease in mortality was
noted.780 The HEMO study, a large RCT comparing two
different dialysis doses in CKD, also could not demonstrate a
further reduction of mortality with equilibrated Kt/V of 1.43
compared to 1.16.781 If we assume that AKI patients should
receive at least the same dose as CKD patients, it seems
reasonable to recommend a thrice-weekly Kt/V of 1.3 or a
weekly Kt/V of 3.9 (assuming at least thrice-weekly
treatment), which also represents the lowest dose in the
largest randomized trial in AKI (ARFTN study). Whether
specific subgroups of AKI patients, such as those with
hypercatabolism, may benefit from higher doses will require
further investigation.
In conclusion, there are only two adequately designed and
executed RCTs testing intermittent or extended RRT dose in
AKI. Neither study showed improvement in mortality or renal
recovery when the dialysis dose was increased, either by
increasing Kt/V above 3.9 weekly or by achieving a plasma urea
target below 90mg/dl (15mmol/l) in AKI patients. However,
consistent with the data on dose of IHD in CKD, and consistent
with the lower-dose arm in the ARFTN study, we recommend
thrice-weekly Kt/Vof 1.3 or a weekly Kt/Vof 3.9 for IHD in AKI.
Seven RCTs have investigated the role of CRRT dose in
AKI (Suppl Tables 37 and 38).531,562,563,768–770,772 While
earlier single-center trials showed mixed results, two large
multicenter trials have reached remarkably consistent con-
clusions concerning the dose of CRRT that should be
provided to critically ill patients with AKI.
The ARFTN study563 compared standard-intensity
predilution CVVHDF with a prescribed effluent flow of
20ml/kg/h to high-intensity CVVHDF at 35ml/kg/h. As dis-
cussed in Recommendation 5.8.3 rationale, there were no
differences in outcomes between the two study arms.
Importantly, more than 95% of the prescribed dose of CRRT
was delivered in the less-intensive group. This represents a
considerably greater intensity of delivered dose than is
typically seen in clinical practice. As in chronic dialysis,
studies in CRRT have shown that delivery usually falls
substantially short of the prescribed dose.782 Thus, it will
usually be necessary to prescribe a high dose of CRRT in
order to achieve a specific target. For example, in order to
achieve a delivered dose of 20–25ml/kg/h, it is likely that the
prescription will need to be in the range of 25–30ml/kg/h.
The Randomized Evaluation of Normal vs. Augmented Level
of RRT study was conducted in 35 centers in Australia and
New Zealand.562 It compared the effects of postdilution
CVVHDF at doses of 25 and 40ml/kg/h on 28- and 90-day
mortality rates in 1464 AKI patients. The delivered dose was
88% and 84% of prescribed in the low- and high-dose
groups, respectively. As in the ARFTN study, there was no
difference in 28- or 90-day mortality between the two groups.
Apart from a higher incidence of hypophosphatemia in the
high-dose group, the complication rate was similar.562
In conclusion, there are now consistent data from two
large multicenter trials showing no benefits of increa-
sing CRRT doses in AKI patients above effluent flows of
20–25ml/kg/h. In clinical practice, in order to achieve a
delivered dose of 20–25ml/kg/h, it is generally necessary to
prescribe in the range of 25–30ml/kg/h, and to minimize
interruptions in CRRT.
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Additional considerations
In patients who do not achieve the target dose of RRT,
despite optimization of the initial modality, a switch to
another modality or the combination of different modalities
should be considered.
Although there are insufficient data supporting a
recommendation for elevated RRT doses in patients with
AKI and septic shock, limited data suggest that a higher
dose might be beneficial in some patients. A small single-
center RCT was conducted in 20 patients with septic shock
and AKI. Patients were randomized to either high-
volume (effluent flow of 65ml/kg/h) or low-volume CVVH
(effluent flow of 35ml/kg/h). The primary end-point was
vasopressor dose required to maintain mean arterial pressure
at 65mm Hg. Mean norepinephrine dose decreased more
rapidly after 24 hours of high-volume as compared to
low-volume CVVH treatment. Survival on day 28 was not
affected.783
RESEARCH RECOMMENDATIONS
K Determine the optimal dose parameter that should be
used in future trials comparing different intensities of
dialysis in AKI patients. Some possible methods to
explore are on-line Kt/V urea, urea reduction ratios, or
application of the concept of corrected equivalent renal
urea clearance for solute removal measurement and
ultrafiltration effluent volume, or substitution fluid
volume normalized by body weight and time for CRRT.
Other aspects of intensity should also be studied, e.g.,
fluid control and acid-base and electrolyte balance. The
comparators might be the standard ways to measure dose
as Kt/Vor prescribed effluent volume. Suggested outcome
parameters are 60- to 90-day mortality, ICU and hospital
LOS, and recovery of kidney function.
K Determine the optimal dose of RRT in AKI in homo-
geneous subpopulations, such as cardiac surgery or sepsis
patients, and separately in ICU and non-ICU patients.
Future RCTs should be controlled for timing of RRT
initiation and, perhaps, for general care of patients
(antibiotics, nutrition, kind and indication for vasoactive
drugs, mode of mechanical ventilation). Studies should
also assess the efficiency of RRT (since dose does not
necessarily mean efficiency), assessing control of BUN,
creatinine, fluid balance, and acid-base and electrolyte
status. The comparators might be different efficiency
targets. The suggested outcomes are 60- to 90-day morta-
lity, need for vasopressor drugs, time on mechanical
ventilation, ICU and hospital stay, and renal recovery.
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